Green Thumb Industries (GTBIF +0.00%) has only pulled back slightly in the months following last April's short-lived run-up among marijuana stocks. Yet while the shares have held fairly well, don't assume this means the stock is fairly priced at present levels.
Rather, considering Green Thumb's operating performance and other fundamentals, it's arguably a stronger choice among investors bullish on eventual regulatory clarity regarding U.S. federal law and the commercial sale of cannabis products.
Image source: Getty Images.
Why Green Thumb stands out While most popular cannabis stocks are based in Canada, Green Thumb is based in Chicago and ranks as one of the more high-profile multistate operators (MSOs). MSOs own and operate marijuana businesses licensed at the U.S. state level. While Canada-based operators, still limited in their ability to enter the U.S. market, continue struggling to reach profitability, MSOs like Green Thumb have already demonstrated consistent profitability.
Green Thumb, for instance, has reported GAAP profitability since 2020. Alongside a demonstrated track record of profitability, the company has a catalyst in place that could significantly increase profitability going forward. Earlier this year, Green Thumb renegotiated its licensing deal with 50%-owned Rythm (RYM 0.23%). Now that it is paying a flat licensing fee for Rythm's trademarks rather than a set percentage, the company has greater operating leverage. This could produce the sort of earnings growth that enables shares to double from current prices.
Today's Change
(
0.00
%) $
0.00
Current Price
$
7.60
Additional catalysts to consider Alongside the aforementioned strengths are a few more that could prove key in driving its shares' next big move higher. For instance, Green Thumb is one of several MSOs that have received a conditional license, permitting it to operate within Texas' upcoming legalized medical cannabis market.
The company also continues aggressively buying back stock, recently increasing its share repurchase program ceiling by $100 million, equivalent to around 6% of its total share count. Even as the stock seems pricey at 38.8 times forward earnings, Green Thumb's perfect storm of bullish catalysts suggests that analysts underestimate the company's further profitability. Again, if you want exposure to the marijuana legalization trend, MSOs like Green Thumb remain the stronger choice.
Thomas Niel has no position in any of the stocks mentioned. The Motley Fool recommends Green Thumb Industries. The Motley Fool has a disclosure policy.
Artificial intelligence is creating some of the biggest winners on Wall Street. Investors have poured into chipmakers, cloud providers, and memory players racing to capitalize on the AI boom. But another group of businesses is quietly benefiting from this trend: cybersecurity companies.
After all, every new AI tool creates a new security challenge. As businesses rush to adopt AI, they must also protect their systems, data, and applications from new threats. That dynamic could create a significant opportunity for SentinelOne (S 0.43%), a cybersecurity company that sits at the intersection of two powerful trends: AI and security.
Image source: Getty Images.
AI is creating a new cybersecurity race Technology shifts often create new security challenges. The rise of the internet gave birth to modern cybersecurity. The move to cloud computing created an entirely new market for cloud security. Now AI is doing the same thing. Businesses are embedding AI into customer service, software development, data analysis, and daily operations. Some companies are even deploying AI agents that can perform tasks with limited human involvement.
These tools can improve productivity, but they also create new risks. Sensitive information can flow into AI systems. Hackers can target AI applications. Automated agents can gain access to critical systems and become attractive targets for cybercriminals. In other words, the more businesses rely on AI, the more important security becomes. That's where SentinelOne comes in.
Today's Change
(
-0.43
%) $
-0.07
Current Price
$
17.52
SentinelOne is more than an antivirus company Many investors still think of SentinelOne as an endpoint security company that protects laptops and servers from cyberattacks. But that's just part of the story. Today, SentinelOne offers a broader cybersecurity platform called Singularity. The platform helps organizations protect devices, cloud environments, user identities, data, and AI-powered applications from cyber threats.
In other words, the company is trying to become a one-stop security platform rather than a single-product vendor. That's an important distinction because platform companies often enjoy larger opportunities than point-solution providers. Once customers adopt a platform, they tend to purchase additional products over time, making those relationships more valuable.
That leads directly to SentinelOne's business model.
A business model built to grow with customers SentinelOne generates most of its revenue through subscriptions. Customers pay recurring fees to use the company's cybersecurity platform. That creates predictable revenue and long-term customer relationships. In the latest quarter, annualized recurring revenue reached $1.2 billion, up 23% year over year.
The real opportunity goes beyond winning a customer once. A company might initially adopt SentinelOne to protect employee devices. Later, that same customer may add cloud security, identity protection, threat detection, data analytics, and other services.
As customers adopt more products, SentinelOne increases revenue without needing to find entirely new customers. Many of the most successful software companies have used this playbook. They land a customer with one product and expand the relationship over many years.
For SentinelOne, that strategy could become increasingly valuable as cybersecurity needs grow more complex.
SentinelOne is also using AI to improve cybersecurity The AI opportunity doesn't stop at protecting AI systems. SentinelOne is also using AI to make cybersecurity easier and more effective. Traditionally, security teams needed highly trained analysts to investigate threats and respond to attacks. That process often required navigating complex tools and analyzing massive amounts of data.
SentinelOne's Purple AI platform aims to simplify that work. Instead of searching through dashboards and databases, security teams can ask questions in plain language and receive actionable insights. The technology can help automate investigations, accelerate responses, and improve productivity.
In many ways, SentinelOne is benefiting from AI on both sides of the equation. AI is creating new security challenges and helping solve them.
What does it mean for investors? Most investors think of AI investment opportunities as just being about chips, data centers, and software applications. But AI also needs security. As businesses deploy more AI tools, they will likely spend more money protecting the systems, data, and applications that power them.
SentinelOne's subscription-based business model, expanding cybersecurity platform, and growing AI capabilities position it to benefit from that trend. That may be the reason so many investors are talking about SentinelOne right now.
Arm Holdings (NASDAQ:ARM | ARM Price Prediction) has been one of 2026’s most dramatic stories, ripping from a January low near $105 to a record $452.70 in June before giving back gains.
With shares now near $315, the question is whether the AI CPU thesis still has room to run or if the easy money has already been made. Our proprietary model says there is more upside, but not the kind investors have gotten used to.
Our 24/7 Wall St. Price Target for Arm The Arm Holdings story is fundamentally about becoming the default CPU architecture of the agentic AI data center. Our 24/7 Wall St. price target for Arm is $344.98, implying 9.42% upside from the current price of $315.28. Our recommendation is buy with a confidence level of 90%.
Metric Value Current Price $315.28 24/7 Wall St. Price Target $344.98 Upside 9.42% Recommendation BUY Confidence Level 90% A Wild Ride From $105 to $452 and Back Arm is up 188.43% year to date and 103.89% over the past year, yet the last month has been brutal. Shares are down 21.71% over the past 30 days and 9.33% in the past week, currently sitting 35% below the 52-week high of $452.70. A 10.1% drop on June 23 during a broader semiconductor rout, combined with a New Street Research downgrade to Neutral and executive insider selling, triggered the pullback.
The fundamentals remain strong. Q4 FY2026 revenue hit $1.49 billion, up 20.1% YoY, with non-GAAP EPS of $0.60 beating consensus. Full-year FY2026 revenue reached $4.92 billion (+22.79%), marking a third consecutive year of 20%+ growth. Next earnings land July 29, 2026.
The Case for $448 and Higher Our bull case final price sits at $448.25, a 42.17% return. The catalyst is Arm AGI CPU, the company’s first data center production silicon. Management flagged more than $2 billion in customer demand across FY2027-FY2028 and a $100+ billion data center CPU TAM by 2030.
Meta is lead partner, and Google, NVIDIA, Microsoft, Oracle, and OpenAI are all building Arm-based silicon. Wall Street bulls have raised targets: TD Cowen to $475, UBS to $470, and Mizuho to $500, targeting $15 billion in agentic AI CPU revenue by fiscal 2031.
The same investor newsletter that told subscribers to buy Amazon in 2002, Netflix in 2004, and Nvidia in 2005 still publishes two new stock picks every month. Over 23 years, Motley Fool's Stock Advisor has more than quadrupled the S&P 500. New members get this month's picks, the Top 10 Rankings, and a 30-day money-back guarantee. Click here to unlock their next top stocks while new members are still being accepted.
What Could Go Wrong The bear case lands at $268.49, a 14.84% loss. Valuation is the elephant in the room. Arm trades at a trailing P/E of 402 and a forward P/E of 154. Non-GAAP operating margin compressed from 52.8% to 49.1% as R&D surged 43% YoY to $1.911 billion.
Bulls argue this is deliberate investment to capture the agentic AI opportunity, and the FY2026 free cash flow jump of 395.5% supports that framing. Other risks include the Qualcomm/Nuvia trial in Q4 CY2026, 25% U.S. semiconductor tariffs, and an FTC antitrust investigation reported in May.
The Setup: Constructive Above $300, More Compelling Below Our 24/7 Wall St. price target for Arm is $344.98, a buy at 90% confidence. The bull thesis strengthens if the July 29 earnings report validates the $1.26 billion Q1 FY2027 revenue guide and hyperscaler CPU share holds near 50%.
The thesis weakens if margins compress further without a clear royalty inflection or if the Qualcomm ruling goes against Arm. At this price, the risk/reward tilts positive.
Here is where our model projects Arm could trade in the coming years, assuming Armv9 royalty rates expand and AGI CPU adoption tracks management’s roadmap.
Year 24/7 Wall St. Price Target 2026 $344.98 2027 $378 2028 $405 2029 $425 2030 $442.80 These projections assume Arm continues executing on its AGI CPU roadmap and hyperscaler design wins. Significant upside could result from Meta’s personal superintelligence rollout scaling to its 3B+ user base, while downside risk centers on litigation outcomes and China export policy.
If You'd Bought Amazon When the Motley Fool Said To…In September 2002, Stock Advisor told subscribers to buy Amazon. In December 2004, Netflix. In April 2005, Nvidia. The newsletter still publishes two new stock picks every month — and over 23 years, has more than quadrupled the S&P 500. Here's how to get this month's picks:
- Join Stock Advisor for one year, with a 30-day money-back guarantee
- Get this month's two new picks — plus the Top 10 Rankings and the full historical pick list
- Read the analysis, decide for yourself, and trade through your own brokerage
Five years from now, you'll probably wish you'd bought this month's picks. Don't miss them.
Growth for artificial intelligence (AI) cloud infrastructure company Nebius Group (NBIS 6.09%) has exploded over the last year, and investors have poured into the stock. A nearly 20% surge in shares in June reversed course in July, though, and investors should continue to expect volatility of this kind.
Nebius stock jumped 19.5% in June, according to data provided by S&P Global Market Intelligence. But it crashed nearly the same amount in the first trading week of July. Here's what investors need to know, and what they should expect ahead.
Image source: Nebius Group.
Building out capacity Investors have been attracted to Nebius stock in droves because of its spectacular growth rates. In its May earnings report, the company said it was again raising its guidance for contracted power capacity to support its data centers, which provide cloud computing infrastructure for AI model development and growth.
That guidance has soared since last August, from at least 1 gigawatt (GW) to over 4 GW. In May, Nebius said it has already secured as much as 1.2 GW of power and land for an AI factory at a new site in Pennsylvania.
Investors continued to boost Nebius stock when it announced it would also partner with fuel cell maker Bloom Energy to install additional power capacity for its data center build-out.
What to make of Nebius stock Revenue has grown stunningly alongside Nebius' data center expansion.
From sales of just $105 million in Q2 a year ago, the company reached an annual revenue run rate of $1.25 billion by the fourth quarter. That remarkable growth rate continues to accelerate. Management now anticipates exceeding $3 billion in revenue for 2026, concluding the year at a rate that could more than double once again in 2027.
Today's Change
(
-6.09
%) $
-13.96
Current Price
$
215.22
But the stock movement has also anticipated that growth, with shares rising more than 150% year to date and more than quadrupling over the last 12 months. It has reached a market cap of about $55 billion, which puts it at a lofty valuation even for its expected 2027 sales.
While demand is extremely strong, competitors like CoreWeave are also in the space. Any sign of a slowdown in spending for cloud capacity will likely hit shares of companies like Nebius and CoreWeave disproportionately compared to the tech sector as a whole.
That makes it a good candidate for investing over time. Long-term investors can purchase more as the stock corrects along the way. There's a good chance that better opportunities will come with the volatility.
Howard Smith has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Bloom Energy. The Motley Fool has a disclosure policy.
There's a new stablecoin in town that wants to shake up the industry. On June 30, a consortium of over 140 organizations announced the launch of Open USD, which has an enticing offer for partners. It proposes joint governance and sharing the interest it earns on its reserves with its partners, as well as free Open USD minting and redemptions.
Image source: Getty Images.
Circle Internet Group (CRCL +4.20%), which issues USD Coin, fell 22% over the 48 hours following the announcement, though it has since pared its losses.
So, is this another flash-in-the-pan token that will fall away like many stablecoin projects have? Or could it take market share from the two dominant players, USDC and Tether?
What is Open USD? The Open Standard consortium says it will launch Open USD, its dollar-pegged stablecoin, later this year. The list of major companies on board is impressive, including Visa (V +2.87%), Mastercard, BlackRock, Alphabet, Coinbase (COIN +3.92%), and more. Given that Coinbase was one of the original forces behind USDC and the crypto firm still shares part of Circle's revenue, its participation raised eyebrows.
Open USD's yield revenue-sharing promise also goes against the grain. By law, U.S. stablecoin firms must back each token they issue with readily accessible reserves, and they can earn interest on those reserves. Circle holds the majority of its assets in U.S. Treasuries, and its reserve yield accounted for $2.63 billion of its total $2.75 billion in revenue in 2025. Investors are worried that Open USD could challenge that stream.
Is the writing on the wall for Circle? Things can turn on a dime in the cryptocurrency and stablecoin markets, particularly because speculation often drives price action. However, the dramatic drop in Circle's stock following Open USD's announcement seems overblown for a stablecoin that hasn't even launched. Open Standard won't be able to replicate Circle's regulatory progress nor its payment network overnight, if at all.
Today's Change
(
4.20
%) $
2.60
Current Price
$
64.55
On a practical level, a consortium of 140 names is impressive, but getting buy-in on key decisions will be a challenge. I have enough trouble organizing an annual holiday with 10 friends -- if that feels like herding cats, I can only imagine the behind-the-scenes wrangling it will take to get those big banks, payment processors, crypto firms, and tech companies to bring Open USD to market.
Plus, neither Tether's dominance nor Circle's first-mover advantage in the U.S. will be easy to shake, as other high-profile stablecoin projects have discovered. Tether launched in 2014 and, despite being dogged by questions about how it handles its reserve funds, there are still $184 billion USDT in circulation -- almost 60% of the total. Circle's USDC ranks second at $73 billion, while the others barely register. For example, PayPal launched PayPal USD in 2023, and it has issued only $2.75 billion in tokens since then.
Can stablecoins achieve their potential? The bigger question is whether the stablecoin industry can really grow at the rate many predict. Issuance soared last year, but growth has slowed in 2026. The market could be worth trillions of dollars, but it depends on stablecoins becoming part of people's day-to-day money management. There's huge potential, but rewiring payment infrastructure takes time.
I am not buying the Circle dip, but that's got nothing to do with Open USD. I want to see how the stablecoin sector evolves, and right now, I think established players like Visa, which is embracing blockchain technology, or Chainlink (LINK +3.05%), the oracle crypto that provides essential data for on-chain and real-world operations, have more potential.
Emma Newbery has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Alphabet, BlackRock, Chainlink, Mastercard, PayPal, and Visa. The Motley Fool recommends Coinbase Global and recommends the following options: short September 2026 $47.50 calls on PayPal. The Motley Fool has a disclosure policy.
The dust has settled, and Space Exploration Technologies (SPCX +2.69%), or SpaceX, has been trading on public markets for a few weeks, with a market value between $1.5 trillion and $2.5 trillion. As of this writing on June 30, the space stock and artificial intelligence (AI) upstart now has a market cap of $2.25 trillion, making it the seventh-most valuable company in the world.
But if you look at the underlying financials, SpaceX is actually much smaller than the other megacap technology companies. Does that make the stock officially overvalued?
Today's Change
(
2.69
%) $
4.24
Current Price
$
161.78
Huge growth opportunity ahead of it SpaceX's total revenue was just $18.7 billion in 2026, which is significantly below the hundreds of billions in revenue that other trillion-dollar market cap stocks like Alphabet, Microsoft, and Apple generate annually. It generates $4 billion in launch revenue, $11.4 billion from its Starlink satellite internet business, and $3.2 billion in AI services revenue.
However, there is significant promise for these businesses to grow in the years ahead. Starlink revenue grew 50% year over year in 2025, and it has a large addressable market to tackle, along with promised innovations to deliver direct-to-device connectivity in the future. AI revenue should begin to grow rapidly in 2026, with new contracts totaling $27.8 billion in annual revenue for data center services. It just acquired Cursor to compete in the AI coding race, which should boost revenue as well.
Lastly, the massive Starship rocket is getting closer to commercialization, which will not only boost launch revenues but also increase capacity to bring Starlink satellites into orbit.
Image source: Getty Images.
Risks of relying on AI and satellite internet While there is a massive opportunity in satellite internet and AI services, SpaceX will be operating in highly competitive fields in the years to come. AI data centers are being aggressively built by many of the megacap technology providers, including a current SpaceX customer, Alphabet. These contracts can be cut at any point with 90 days' notice, meaning if the overbuilding of data centers eventually occurs, SpaceX's AI revenue may be in for a world of hurt.
With satellite internet, SpaceX is the dominant player today but has many competitors nipping at its heels, such as Amazon, Rocket Lab, and AST SpaceMobile, that are investing billions to deploy their own satellite internet constellations. A long-term addressable market in the hundreds of billions will likely not all flow to SpaceX, despite its current lead in the race.
There is no doubt that SpaceX is tackling massive markets in satellite internet and AI; it's just that there is massive competition for a business that generated under $20 billion in revenue in 2025. The company now has a rock-solid balance sheet after the largest IPO in history, which will be necessary to aggressively spend to win in these new markets, with $9 billion in cash burned in Q1 alone.
SpaceX's consolidated business is also not high margin, with a total gross margin just above 50% in 2025 and a $2.5 billion operating loss. This is the largest stock by market cap in history that is not profitable. Even if you just value SpaceX on its revenue, the stock currently trades at a price-to-sales ratio (P/S) above 100, which is one of the most extreme revenue multiples in market history. The stock is valued as if it were already doing hundreds of billions in revenue, when that may not happen for a decade or longer.
Unless SpaceX can actually achieve its dream of the space economy and AI within a few years, the stock looks wildly overvalued at a market cap of $2.25 trillion.
Brett Schafer has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends AST SpaceMobile, Alphabet, Amazon, Apple, Microsoft, and Rocket Lab. The Motley Fool has a disclosure policy.
Image Credits:Samuel Boivin/NurPhoto / Getty Images China’s Alibaba will ban employees from using Anthropic’s programming tool Claude Code, starting on July 10, according to multiple reports.
Anthropic already prohibits Chinese companies, as well as foreign entities owned by those companies, from using its models. The company has reportedly been working to close loopholes that allow Chinese users to access Claude.
According to a recent Reddit post, some of that loophole-closing involved a version of Claude Code that could secretly identify Chinese users. Anthropic’s Thariq Shihipar said in a post on X that this was “an experiment we launched in March that was meant to prevent account abuse from unauthorized resellers and protect against distillation.” (Distillation is a practice where AI models are trained on the outputs of other models.)
“The team has landed stronger mitigations since then and we’ve actually been meaning to take this down for a while,” Shihipar said.
Nonetheless, Alibaba has reportedly classified Claude Code as high-risk software and is instructing employees to use the company’s own Qoder tool instead.
Rainbow Rare Earths Ltd (LSE:RBW, OTC:RBWRF, FRA:RR1) says it has significantly simplified the process flow sheet for its phosphogypsum rare earths recovery project, a move expected to reduce costs and improve plant operability ahead of the definitive feasibility study.
Chief executive George Bennett and technical director Dave Dodd joined Proactive to discuss the technical breakthroughs behind the redesign, the remaining DFS work and the project's potential production of high-purity NdPr and heavy rare earth products.
Watch the full interview below and read the transcript underneath.
Proactive: I'm joined by Rainbow Rare Earths Ltd (LSE:RBW, OTC:RBWRF) CEO George Bennett as well as technical director Dave Dodd. Gents, very good to speak with you. George, looking very smart today, are you going somewhere?
George Bennett: Yes, I've been invited by the U.S. Embassy in Pretoria to celebrate the Fourth of July with them. Rainbow has a very close relationship with the U.S. government, hence my invitation by the embassy in Pretoria today.
Proactive: David, turning to today's news, you've simplified the flow sheet quite dramatically. What's the biggest technical breakthrough that gave you the confidence to do that?
Dave Dodd: The breakthrough came from understanding how to control the purity of the leach solution from phosphogypsum, particularly the fluorine present in the phosphogypsum stacks. Previously we had a weak acid leach and fluoride recovery circuit ahead of the rare earth leach, but we've established that we can control fluorine simply by adding silica, which complexes with the fluorine so it doesn't affect the rare earth leach. That has allowed us to eliminate a significant part of the process.
We've also introduced continuous ion exchange (CIX) for the primary recovery of rare earths from the leach solution. This replaces a much more complicated process involving fluorine precipitation, acid baking and water leaching. Those two changes have greatly simplified our flow sheet.
Proactive: George, from an investor's perspective, what does the simpler flow sheet actually mean? Lower costs, lower risk or a faster route to production?
George Bennett: The first two are the key benefits. We believe these optimisations have reduced both capital expenditure and operating costs, helping to keep capital within the figures previously communicated to the market in our December 2024 update.
Just as importantly, the plant is now much more operable from both an HSE and operational perspective. Rare earth processing plants are well known for their complexity, and there are very few operating in the Western world. We believe these optimisations have simplified our flow sheet, improving operability, reducing execution risk and helping ensure we achieve both the planned throughput and targeted rare earth recovery from the phosphogypsum.
Proactive: Dave, the project is recovering rare earths from a waste product rather than mining fresh ore. What have been the biggest technical challenges in making that work at commercial scale?
Dave Dodd: One of the keys has been developing a process that uses standard, proven industry technologies, even though we've combined them in a different way. That makes scaling the process relatively straightforward.
The biggest technical challenges have been understanding acid behaviour during the leaching process and managing impurities, particularly calcium. Because we're processing gypsum, which is calcium sulphate, the system is always calcium saturated. Understanding and controlling calcium behaviour has been critical, and we believe we've now developed a strong understanding of those aspects.
Proactive: George, with around three-quarters of the process now locked in, what's left to prove before investors can look forward to the completed DFS?
George Bennett: There's nothing fundamentally left to prove because we're using standard downstream solvent extraction. The remaining work focuses on optimising the interface between the eluate from the Continuous Ion Exchange circuit and the solvent extraction circuit, ensuring impurity levels are exactly where they need to be.
The solvent extraction circuit will produce separated NdPr at more than 99.5% purity, together with our heavy rare earth concentrate. That product contains approximately 60 tonnes per annum of dysprosium, 20 tonnes per annum of terbium and around 130 tonnes per annum of yttrium, all of which are highly sought-after heavy rare earths.
Proactive: George, David, thanks for the update. We look forward to hearing more about your progress. George, enjoy the Fourth of July celebrations.
Delivra Health Brands Inc. (TSX-V:DHB, OTCQB:DHBUF, FRA:3F0) CEO Gord Davey talked with Proactive about the company's launch of LivRelief Itch Cream, a new product designed to provide relief for people suffering from itching associated with psoriasis, eczema, bug bites and skin rashes.
During the interview, Davey explained that LivRelief Itch Cream is based on a patented process and combines itch relief with moisturizing properties to help soothe irritated skin. The product is designed for individuals dealing with persistent itching and skin discomfort, offering support during what Davey described as the "irritable stage" of these common conditions.
Davey highlighted that the cream incorporates Delivra Health Brands' patented delivery system, which is intended to penetrate the skin and help alleviate itching and discomfort caused by constant scratching. He noted that the addition of moisturizing agents is an important feature, helping to support skin health while providing relief.
The discussion also covered the market opportunity for the product. Referencing data from the Canadian Dermatology Association, the interview noted that approximately 17% of Canadians experience some form of itching during their lives. Davey said the company conducts extensive market research before launching new products and develops solutions that respond to consumer demand.
Proactive: Welcome back inside our Proactive newsroom. Joining me now is Gord Davey, CEO of Delivra Health Brands. Gord, it's great to see you again. How are you?
Gord Davey: Hey, as always it's great to see you and excited to speak with you today.
Especially because you're launching a brand new product. Congratulations. This is an itch relief cream, and there are so many people looking for solutions to persistent itching. Tell us about it.
This is really exciting. This is a patented process that we have, and it's called LivRelief Itch Cream. Anyone with psoriasis, eczema, bug bites or rashes can benefit from this product. It helps people get through that irritable stage and also contains a moisturizing agent to help soothe the skin while alleviating itching. It's a wonderful product and we're happy to be launching it very shortly.
I understand the product was developed with people who have sensitive skin in mind. Features like hypoallergenic formulations are important to consumers.
They really are. When people are suffering from these ailments, it's important to find the right product. It needs to help with the itch while also moisturizing the affected area to help prevent the issue from returning. One of the great things about this product is that it uses Delivra's patented delivery system, which gets into the skin and helps alleviate itching and discomfort associated with constant scratching. Again, it's a wonderful product that we're just bringing to market.
The Canadian Dermatology Association says about 17% of Canadians will experience some type of itching during their lives. That sounds like a significant market opportunity.
That's one of the reasons we're making this product. Whenever we develop new items, we conduct market research behind these types of products. This is another patented process from Dr. Joe Gabriel, whose company we acquired. The products we're launching now are ones the marketplace has been asking for. Again, whether it's psoriasis, eczema or bug bites, this is a product designed to help people through those issues.
Talk about the innovation side of the business and your commitment to developing products consumers need.
That's exactly what we do. We are a health and wellness company dedicated to innovation. We focus heavily on market data and market research when developing products, and we will continue to launch new products going forward. This is one we've been working on for quite some time, and we're very pleased that it's finally ready to reach the market.
It's the LivRelief Itch Cream. Gord, thanks for the update.
Thank you very much. As always, it's a pleasure talking to you.
Gord Davey, CEO of Delivra Health Brands.
Quotes have been lightly edited for clarity and style
Trillion Energy International Inc. (CSE:TCF, OTCQB:TRLEF, FRA:Z620) earlier this week announced the completion of technical field scouting work on its M47 exploration licence in Türkiye, advancing preparations for future seismic acquisition and potential oil field development.
Speaking with Proactive, President Scott Lower said the field programme represented an important step in determining the optimal placement of seismic survey lines, which will ultimately guide future drilling locations across the licence.
Lower said the company envisaged substantial long-term development across the block, noting that the objective was to position the project for significant drilling activity over the coming years. He explained that careful seismic planning was essential because drilling represented the largest capital investment in the project and accurate well placement could materially improve the probability of targeting productive reservoirs.
He said the geological complexity of the region, which includes anticlines, folds and thrust structures, made high-quality seismic interpretation particularly important. The latest field work builds upon historical gravity surveys and three earlier seismic programmes while refining areas where previous interpretations remained uncertain.
Lower highlighted the northern portion of the licence as the company's immediate area of interest, stating that it already contains a proven oil discovery. He said 27 million barrels of recoverable oil have been discovered net to Trillion Energy and noted that development planning for the area contemplates more than 50 wells over the next one to two years.
According to Lower, this northern development area is expected to provide the company's initial production as development progresses. Following completion of the geological model, Trillion Energy intends to identify drilling locations designed to maximise reservoir potential.
He added that the planned wells are expected to produce between 500 and 1,000 barrels of oil per day, providing the foundation for future operating cash flow once development commences.
Looking ahead, Lower said the next catalysts for investors include completion of geological modelling, selection of final drilling locations, advancement of the seismic programme and progression toward field development. He also identified first sustainable production as a key milestone as the company works to convert its discovered resource into commercial output.
Custom Health Holdings Inc (TSX:CHLT) CEO Shane Bishop talked with Proactive about the company's technology-enabled pharmacy model, its expansion strategy and the opportunities ahead following its recent TSX listing.
Proactive: Welcome back inside our Proactive newsroom. Joining me today is Shane Bishop, CEO of Custom Health. Shane, great to see you.
Shane Bishop: Thank you. I appreciate the invitation and look forward to the conversation.
Custom Health has an interesting history. It was founded to solve challenges in long-term healthcare. Can you explain how the company began?
I'm a pharmacist by profession, and early on we identified a systemic problem between pharmacy and nursing in long-term care around medication administration. We developed technology to improve the accuracy of that process. That original solution remains part of our business today, but it also became the foundation for expanding our model into patients' homes.
The company has evolved significantly since then. How does Custom Health operate today?
We've built infrastructure that connects pharmacies we own and operate with in-home medication dispensing technology. The device collects patient information up to four times a day, and that information flows into our platform where remote clinicians analyse it. We also integrate with electronic health records and electronic medical records, allowing us to send real-time recommendations to physicians. Our focus is delivering proactive patient care.
What does the patient experience look like at home?
One of our major focus areas is pain management in the United States. We've reduced opioid usage among patients by 27%. Prescriptions are filled through our pharmacies, packaged into specialised medication cartridges and delivered to the patient's home. The dispensing device releases medication at scheduled times, captures an image of the medication for chain-of-custody tracking and asks patients questions, such as their current pain level. About 91% of patients respond. Our clinicians use that information to determine whether medication adjustments may be appropriate and communicate recommendations to physicians to help reduce addiction risk while maintaining effective pain management.
Custom Health recently completed an acquisition. How does that fit into the growth strategy?
We're targeting pharmacy acquisitions in geographies where reimbursement already exists for our model. These are often pharmacies we already work with. Owning the pharmacies gives us greater control over quality and deployment while combining acquisition-driven growth with additional patient volume flowing into the business. We believe that creates an attractive and scalable model.
Will growth primarily come from Canada or the United States?
We expect approximately 80% of our growth to come from the United States because reimbursement for pharmacy-led services is more developed there. Canada also represents an opportunity, but the US will likely remain our primary focus.
The company recently began trading on the TSX under the ticker CHLT. What does becoming a public company mean for Custom Health?
Access to the public markets supports our growth strategy. It allows us to raise equity to expand organically by deploying more devices and building our clinical team, while also strengthening our balance sheet to support pharmacy acquisitions. Public markets also provide flexibility through cash-and-share acquisition structures.
What should investors watch for over the coming year?
Investors should watch for continued growth in key geographies, announcements involving larger healthcare providers and the expansion of our pharmacy footprint. Our strategy combines pharmacy acquisitions with software and technology service revenue, creating a differentiated model that we believe positions the company well for future growth.
Shane, thank you for joining us today.
Thank you. It was great speaking with you.
Quotes have been lightly edited for style and clarity
Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
United Parcel Service (UPS +1.02%) is deeply unloved on Wall Street, with the stock down 50% from its 2022 high. To be fair, the parcel delivery company has been going through a massive business overhaul, and its quarterly earnings results have been pretty tough to read. But it is important to keep in mind what the company is doing and why. The announcement of a $48 million investment in temperature-controlled facilities highlights something big.
UPS is updating its business approach To simplify this industrial giant's turnaround effort, it is basically trying to modernize. That requires spending money to update technology, cut staffing levels, and shutter less efficient facilities. At the same time, however, UPS has been honing in on its best customers, which has required limiting its relationship with high-volume customers that offer only small profit margins.
Image source: Getty Images.
From a high-level view, this overhaul has led to lower revenue and higher costs. Which investors have clearly been worried about. However, there are early signs of success: revenue per package in the U.S. market has been rising despite lower overall revenue in the division. That's exactly the goal. Management is also calling for the second half of 2026 to be the inflection point for the turnaround effort.
UPS is building for the future UPS isn't just moving away from low-margin customers; it is also moving toward high-margin customers. One customer segment earmarked for growth is the healthcare sector. That's why UPS is spending $48 million on 27 temperature-controlled facilities. There is an increasing demand for medications that must be kept at low temperatures during the delivery process, notably including GLP-1 weight-loss drugs.
Today's Change
(
1.02
%) $
1.12
Current Price
$
110.66
This isn't a brand new business; UPS has been using acquisitions to bolster its global position in this sector. However, the key is that healthcare customers offer wider profit margins and attractive growth opportunities. It is far more desirable to invest in moving medicine than to boost operations that just move more low-value boxes.
UPS has a huge 6% dividend yield because investors are worried about the turnaround. That's fair given recent results. But the investment in temperature-controlled facilities highlights the company's long-term strategic focus and opportunity. It is one more sign that UPS could be close to shifting from shrinking its business to growing it. And when that happens, the growth will likely be more impactful because it will come with wider profit margins.
Reuben Gregg Brewer has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends United Parcel Service. The Motley Fool has a disclosure policy.
New York, New York--(Newsfile Corp. - July 4, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of First Solar, Inc. (NASDAQ: FSLR) between February 26, 2025 and February 24, 2026, inclusive (the "Class Period"), of the important August 24, 2026 lead plaintiff deadline.
SO WHAT: If you purchased First Solar securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
WHAT TO DO NEXT: To join the First Solar class action, go to https://rosenlegal.com/cases/first-solar-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 24, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.
DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made materially false and misleading statements and/or failed to disclose that: (1) defendants had overstated First Solar's capacity to manage the impact of U.S. tariff policy on First Solar's business; (2) defendants understated the extent to which its responses to U.S. tariff policy, including the intentional underutilization of production facilities in Malaysia and Vietnam, and attempted relocation of production to the U.S., were likely to negatively impact First Solar's projected performance in the 2026 fiscal year; and (3) as a result, defendants' public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
To join the First Solar class action, go to https://rosenlegal.com/cases/first-solar-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.
Attorney Advertising. Prior results do not guarantee a similar outcome.
-------------------------------
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/303890
Source: The Rosen Law Firm PA
Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.
Albert Einstein called compound interest the eighth wonder of the world, quipping, "He who understands it, earns it... he who doesn't... pays it." Investing in dividend-paying stocks is one way to capitalize on the wonders of compounding. Investors who reinvest their dividends in a company that grows its payout can earn enriching returns.
Realty Income (O +3.15%) prides itself on paying dependable, growing monthly dividends. Here's a look at whether the real estate investment trust (REIT) can help you compound your investment into future riches.
Image source: Getty Images.
A compounding machine Realty Income has been a terrific dividend stock over the years. The REIT has increased its monthly payment 135 times since its public market listing in 1994, including the past 115 consecutive quarters. It has grown its dividend at a 4.1% compound annual rate during that three-decade period.
Investors who reinvested their dividends have earned a robust 13.6% compound annual return from the REIT since 1994. To put that return into perspective, an investor who bought $25,000 of Realty Income stock in 1994 would have seen that initial investment grow to nearly $1.2 million.
Today's Change
(
3.15
%) $
1.95
Current Price
$
63.77
Can Realty Income continue to compound? While Realty Income has clearly made investors rich through compounding since it went public, that past performance doesn't guarantee it will deliver similar results in the future. Here's a realistic look at how the REIT might perform over the next several decades.
Realty Income currently pays a dividend yield of more than 5%. That high-yielding payout provides a very sustainable base return. Realty Income generates very stable income from its diversified portfolio of net-leased real estate. Meanwhile, the REIT has a conservative dividend payout ratio (around 70%) and one of the strongest balance sheets in the sector. That gives it the financial strength to continue investing in growing its portfolio of income-producing real estate, which is the key to increasing its dividend.
The REIT has historically grown its adjusted funds from operations (AFFO) per share at a 5% annual rate through a combination of rent growth and new investments, supporting its 4.1% compound annual dividend growth rate. Realty Income has been positioning itself to deliver higher future growth through a series of strategic initiatives. It has formed several strategic private capital partnerships that should accelerate AFFO per share growth through capital-light revenue, such as management fee income. The REIT is also forming strategic partnerships to capitalize on the large, fast-growing data center segment. These initiatives could enable the REIT to grow its AFFO at a mid-to-high single-digit rate in the future.
With a 5%+ current yield and the potential to deliver 5%+ annual AFFO per share growth in the future, Realty Income could produce a more than 10% annualized total return (assuming no change in its valuation multiple). That level of return could certainly make you rich through long-term compounding. For example, if you invested $5,000 into Realty Income each year and it delivered an average annual return of 11%, the REIT could grow your investment to over $1.1 million in 30 years.
An enriching dividend stock Realty Income has made long-term investors rich by steadily growing its monthly dividend. The REIT is in a strong position to continue compounding shareholder value going forward, driven by its new strategic capital partnerships and data center investments. That makes it a great dividend stock to buy and hold long-term, as it should steadily create more wealth for shareholders.
While the market has been driven higher by artificial intelligence (AI) stocks over the past few years, these stocks have recently pulled back, creating a potential buying opportunity. The fear is that spending could eventually start to slow.
But right now, hyperscalers (owners of large data centers) have indicated that they are getting strong returns on their investments and that they continue to plan to spend big money building out AI data centers.
Let's look at three AI stocks to buy on this dip.
Image source: Getty Images.
Nvidia: The original AI play No company has benefited more from the AI infrastructure build-out than Nvidia (NVDA 1.39%), which has grown to become the world's largest company by market cap. Its graphics processing units (GPUs) are the primary chips used to train AI models, and its CUDA software, where most foundational AI code has been written, gives it a wide moat in this area.
However, the Nvidia of today is more than just GPUs; it has become a complete AI infrastructure player. It has a strong networking portfolio, which has been one of its fastest-growing areas, while its "acquisition" of Groq brought chips specifically for inference. It's also dived into the data center central processing unit (CPU) market. Together, this now allows it to offer complete systems for specific AI tasks, which should position it for continued strong growth well into the future.
Today's Change
(
-1.39
%) $
-2.75
Current Price
$
194.84
AMD: The AI upstart Advanced Micro Devices (AMD 4.60%) may have lost to Nvidia when it came to AI model training, but the company looks well positioned for inference and agentic AI.
Inference is eventually expected to become larger than training, and AMD's GPUs are much better suited for this task. Inference is much more memory-bound than compute-bound, and AMD's chiplet design allows it to be packaged with more memory. Its recent acquisition of MEXT and its memory optimization technology, and ZT Systems, meanwhile, will allow it to offer complete systems designed for inference. The company already has two large inference partnerships, which should be a major area of growth in the coming years.
On top of that, the company is positioned to be a major beneficiary of agentic AI, which will require a significant increase in the use of CPUs in AI data centers. This will boost AMD, which is a leader in the space and has been taking market share away from rival Intel. AMD is already developing CPUs specifically for agentic AI and sees this growing to be a $120 billion addressable market over the next few years.
Today's Change
(
-4.60
%) $
-24.88
Current Price
$
516.00
Micron: A memory winner The memory market continues to explode higher, and as one of the big three DRAM (dynamic random access memory) makers, Micron Technology (MU 5.68%) continues to be a huge beneficiary. The company just posted incredible numbers for its fiscal third quarter, with revenue surging from $9.3 billion a year ago to $41.5 billion and gross margin expanding to 84.6% from 37.7%.
The demand for high-bandwidth memory (HBM), which is a special form of DRAM packaged with GPUs to optimize performance, remains insatiable, with Micron's supply sold out for 2027 and into 2028. It expects HBM to be a $100 billion market next year. Meanwhile, it has now signed long-term strategic customer agreements that include both HBM and NAND (flash memory) that are non-cancellable, take-or-pay arrangements with annual volume commitments, with some extending until 2030. This should help reduce some of the typical cyclicality of the memory business.
Today's Change
(
-5.68
%) $
-58.69
Current Price
$
973.59
Micron is working to continue increasing capacity, although the market is expected to remain supply constrained for the foreseeable future. Between its SCAs and supply-demand dynamics, this makes the stock a good one to buy after the recent pullback.
MercadoLibre is primed for a rebound after a ~30% stock decline despite accelerating growth, especially in Brazil. I see MELI benefiting from secular Latin American growth, with ~$20B quarterly GMV expanding at a mid-30s pace. MercadoPago, MELI's fintech arm, drives TPV at ~4x GMV and now contributes nearly half of total revenue.
There are four companies in the world worth $3 trillion or more: Apple, Microsoft, Nvidia, and Alphabet. What they have in common is that they either develop the most important consumer hardware on Earth, run the software infrastructure that enterprises depend on, or design the chips that power the AI revolution.
The fifth member of that club is none of those things. Instead, it produces key components for all of them. Taiwan Semiconductor Manufacturing (TSM 2.15%) sits at roughly $2.24 trillion in market value as of late June 2026. That makes it the sixth most valuable company on the planet.
Given the numbers it's putting up right now, the $3 trillion mark is not far away. Here's how it gets there.
Today's Change
(
-2.15
%) $
-9.53
Current Price
$
434.70
The numbers make the case In 2026's first quarter, TSMC reported revenue of $35.9 billion, up 40.6% from the same quarter a year earlier. Net income rose 58.3% year over year. Gross margin came in at 66.2%. Net profit margin was 50.5%. Take a second with that last number. For every dollar TSMC brings in, it keeps fifty cents as profit. That's a level of operational leverage most companies would consider impossible.
For Q2 2026, management guided for revenue between $39 billion and $40.2 billion. The full-year 2026 growth forecast is above 30% in U.S. dollar terms. At that trajectory, TSMC will generate well north of $150 billion in annual revenue this year. If margins hold even close to where they are, the profit picture is extraordinary.
To get from $2.24 trillion to $3 trillion, the stock needs to gain roughly 34%. With earnings compounding at 50% or more year over year, that gap closes quickly.
Why TSMC is the real AI story Everyone focuses on Nvidia when they talk about AI chips, and that's fair. But Nvidia does not manufacture its own chips. Neither does Advanced Micro Devices. Neither does Apple. Every advanced processor in those companies' lineups comes out of a TSMC fab. TSMC has roughly 70% global market share in advanced chip manufacturing, and no competitor is close to challenging that at the most cutting-edge nodes.
Advanced technologies at 7 nanometers (nms) and below now account for 74% of TSMC's wafer revenue. That mix has shifted fast, and it matters because leading-edge nodes carry higher prices and better margins. As AI drives demand for 3nm and eventually 2nm chips, TSMC gets paid more per wafer and keeps more of it.
The AI infrastructure build-out is not a quarter or two of demand. Every hyperscaler is building massive graphics processing unit (GPU) clusters, and every GPU in those clusters is a TSMC chip. Nvidia has Blackwell. Amazon has Trainium. Alphabet's Google has tensor processing units (TPUs). They all flow through TSMC's fabs.
Image source: Getty Images.
Arizona changes the story For years, the argument against owning TSMC was the geopolitical risk. All the important fabs were on Taiwan, and the uncertainty around that geography created what analysts called a "Taiwan discount" on the stock's valuation. That discount is starting to shrink.
TSMC has committed $165 billion to its Arizona expansion, a campus covering more than 2,000 acres with six planned fabs, two advanced packaging facilities, and an R&D center. The first Arizona fab already turned a $514 million profit in its first year of production. Phase two, running at 3nm, is on track for 2027, a full year ahead of the original schedule.
As more production moves to U.S. soil, institutional investors who previously avoided TSM on geopolitical grounds have a reason to buy. That is not a small shift. More buyers chasing the same fundamental story pushes multiples up, which pushes market cap up alongside the earnings growth.
TSMC is not invincible. A serious escalation in Taiwan tensions remains a risk that no analyst can fully price. The company also relies on equipment makers like ASML Holding for the tools it needs to manufacture at leading-edge nodes, which creates supply-chain dependencies. And semiconductor cycles can turn. A broad slowdown in AI infrastructure spending would show up in TSMC's numbers fast.
But if you believe AI is a decade-long build-out, and that someone has to manufacture all those chips, TSMC's path to the $3 trillion club is one of the more visible roads in the market right now.
Micah Zimmerman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends ASML, Advanced Micro Devices, Alphabet, Amazon, Apple, Microsoft, Nvidia, and Taiwan Semiconductor Manufacturing. The Motley Fool has a disclosure policy.
Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
Our Coinbase (NASDAQ:COIN | COIN Price Prediction) call is unabashedly constructive. Shares have been battered in 2026, but the setup into the back half of the year looks compelling if crypto volumes normalize and the cost-out plan sticks.
The 24/7 Wall St. price target for Coinbase is $360.19 over the next 12 months, implying 117.66% upside from $165.48. Our recommendation is buy, with a confidence level of 90%. That is a high-conviction call on a high-beta stock.
24/7 Wall St. Price Target Summary Metric Value Current Price $165.48 24/7 Wall St. Price Target $360.19 Upside 117.66% Recommendation BUY Confidence Level 90% A Brutal Year, With a Turn Off the Lows Coinbase has been a punishing hold. The stock is down 53.31% over the past year and 26.82% year to date, retracing from a 52-week high of $444.64 to a 52-week low of $139.18. Momentum is finally turning: shares are up 16.11% in the past week.
Q1 2026, reported May 7, was the flashpoint. Revenue fell to $1.413 billion, a 30.54% YoY drop, missing consensus. GAAP EPS came in at -$1.49, hammered by $482.4 million in losses on crypto assets held for investment.
Adjusted EBITDA, however, stayed positive at $303.3 million, the 13th consecutive positive quarter. Management announced a 14% headcount reduction targeting $500 million in annualized savings.
Why Bulls See a Breakout Ahead The bull case rests on Coinbase’s “Everything Exchange” expansion into equities, prediction markets, commodities, and FX, alongside the stablecoin franchise. USDC market cap reached an $80 billion all-time high in March 2026, and management sees stablecoins growing from ~$300 billion to $3 trillion by 2030.
Prediction markets are already annualizing $100 million+ in their first two months. Analysts back the setup, with a consensus target of $229.40 and 21 buy ratings against three sells. Our bull-case scenario points to $439.81 over 12 months if volumes reaccelerate and cost cuts flow through.
SoFi Active Invest is offering a limited-time promotion. Open an account, fund it with $50 or more, and you could receive up to $1,000 in complimentary stock for Active Invest accounts. See for yourself by clicking here now.
The Risks Worth Watching Crypto cyclicality is the central risk. Total crypto market cap and trading volumes fell 20%+ QoQ in Q1 2026, and transaction revenue dropped 23% sequentially. The forward P/E of 118x leaves no margin for another volume air-pocket. Prediction markets currently place the highest probability on $175 for July 2026, well below our target.
Insider activity has also skewed toward net selling across 90 recent transactions. In counterfactual defense, bulls would argue those GAAP losses reflect mark-to-market noise on strategic crypto holdings. Adjusted EBITDA and $10.2 billion in cash speak to underlying resilience. Our bear-case scenario still lands at $289.71.
Coinbase Price Prediction 2026-2030 The 24/7 Wall St. price target of $360.19 and buy rating carry a 90% confidence score. The key factor tipping the scale is the combination of a cleaned-up cost base, resilient subscription and services revenue at 44% of net revenue, and a stablecoin engine that keeps growing regardless of trading volumes.
The setup rewards investors who can stomach a beta of 3.32 and want optionality on a crypto reacceleration into 2027. The picture looks less favorable if crypto volumes keep contracting through year-end or if regulatory friction escalates.
Looking further ahead, here is where our model projects Coinbase could trade, assuming current growth trajectories and market conditions hold.
Year 24/7 Wall St. Price Target 2026 $360.19 2027 $540 2028 $780 2029 $1,080 2030 $1,399.78 These projections assume Coinbase continues executing on its Everything Exchange strategy and stablecoin scaling. Significant upside or downside could result from a full crypto cycle turn, tokenized RWA adoption, or a regulatory reversal.
Want Up To $1,000? SoFi Is Giving New Active Invest Users Free StockLooking to grow your money but unsure where to begin? SoFi Active Invest is offering a limited-time promotion—open an account, fund it with $50 or more, and you could receive up to $1,000 in complimentary stock for Active Invest accounts.
From $0 commission trading to fractional shares and automated investing, this app is designed to simplify investing for everyone, whether you’re just starting or already experienced. Its easy to sign up and secure your bonus.
Chubb: Managing Volatile RevenueChubb (CB +2.57%) primarily generates revenue by offering a broad spectrum of commercial property and casualty, agricultural, and life insurance products to individual and corporate clients globally.
It recently entered a partnership with Safe Harbor Marinas and reduced exposure in its shared property business, and it reported 16% net income margin for the quarter ended March 31, 2026.
Travelers Companies: Steady Top-Line TrendsTravelers Companies (TRV +2.30%) primarily earns revenue by providing a comprehensive portfolio of commercial and personal property and casualty insurance products through a network of independent agents and brokers.
It recently launched an artificial intelligence tool for claims analysis and joined a sustainable insurance initiative in California, while recording 14% net income margin for the quarter ended March 31, 2026.
Why Revenue Matters for Retail InvestorsFor financial institutions such as Chubb and Travelers, revenue here refers to interest income plus non-interest income and is not net of interest expense. It serves as a critical baseline indicator of how much money a business brings in before any operational costs are deducted.
Quarterly Revenue for Chubb and Travelers CompaniesQuarter (Period End)Chubb RevenueTravelers Companies RevenueQ2 2024 (June 2024)$13.9 billion$11.3 billionQ3 2024 (Sept. 2024)$15.1 billion$11.9 billionQ4 2024 (Dec. 2024)$14.2 billion$12.0 billionQ1 2025 (March 2025)$13.4 billion$11.8 billionQ2 2025 (June 2025)$14.9 billion$12.1 billionQ3 2025 (Sept. 2025)$16.2 billion$12.5 billionQ4 2025 (Dec. 2025)$15.3 billion$12.4 billionQ1 2026 (March 2026)$14.8 billion$11.9 billionData source: Company filings. Data as of June 23, 2026.
Foolish TakeExamining the revenue trends for insurance giants Chubb and Travelers is a contrast between the former’s greater variability across quarters versus the latter’s quarterly sales consistency. This difference is a result of Chubb’s global operations. Nearly half of its sales come from international markets, exposing the company to fluctuations in foreign currency exchange rates.
Meanwhile, in 2025, Travelers produced 93% of its revenue from the U.S., and its Canada operations were sold at the start of 2026, reducing international exposure even further. As a result, Chubb’s sales are meaningfully higher than Travelers.
While quarterly revenue fluctuations are normal, a trend to look for is rising year-over-year sales. From that perspective, Chubb has experienced stronger growth. Its first-quarter revenue of $14.8 billion was a 10% increase over 2025’s $13.4 billion while Travelers’ sales rose 1% in that time. Given Travelers is U.S.-focused, its revenue won’t see the kind of expansion that Chubb can enjoy from its global presence.
But revenue is not the only focus in evaluating these companies. Another key consideration is net income growth. Here, both performed well in Q1. Chubb’s net income of $2.32 billion was a 74% year-over-year increase. Travelers reported Q1 net income of $1.7 billion, a whopping 333% jump, helping to send its shares to a multi-year high of $342.31.
HP (HPQ 0.34%) and Dell (DELL 7.27%) are both competing in the AI PC market. Both of them have dominated the PC industry for years, but those same computers will soon have built-in AI capabilities.
They both offer AI servers as well, which have become valuable parts of AI infrastructure, but one of these tech stocks looks better than the other. Here's what investors should consider when deciding which stock to buy.
Image source: Getty Images.
HP has a much better valuation Investors who like value stocks should prioritize HP. The company only has an 8.5 P/E ratio, which is much lower than Dell's 31.8 P/E ratio. If the AI theme experiences any slowdowns, HP is more insulated than Dell.
Dell has also enjoyed a much better rally than HP. While Dell has more than tripled year to date, HP is only up by 2% year to date because of a recent correction of more than 20%. The big Dell rally puts the stock at a higher valuation, which makes it riskier for new investors. HP offers the opposite setup, with a recent correction presenting a buying opportunity.
Both companies have been improving their fundamentals in recent quarters, but only one of them has marched higher halfway through 2026. Contrarian investors can benefit if HP reports strong earnings and reinvigorates bullish momentum.
Today's Change
(
-0.34
%) $
-0.07
Current Price
$
21.95
Dell is growing much faster Although Dell has a higher valuation and is more exposed to macroeconomic weaknesses or AI slowdowns thanks to its substantial year-to-date rally, it's the faster-growing company. Dell's AI servers contributed to 88% year-over-year revenue growth in its fiscal 2027 first quarter.
Dell's chief operating officer, Jeff Clarke, told investors to expect $60 billion in AI server revenue in fiscal 2027 and said this guidance shows that "the AI opportunity shows no signs of slowing." Its AI servers delivered 757% year-over-year revenue growth, accounting for more than one-third of total revenue.
HP's 9% year-over-year revenue growth rate in its fiscal 2026 second quarter looks far less attractive in comparison. A low valuation compensates for the lower growth rate, but it shows that Dell is gaining market share much faster.
This trend will likely continue. AI servers are the main catalyst for Dell's growth, but they are a smaller part of HP. The latter's growth story mainly revolves around AI PCs, while that product category has a more limited impact on Dell's financial results.
HP's guidance for its fiscal 2026 third quarter didn't do much to change that picture. The company said it anticipates diluted EPS to range from $0.47 to $0.63, which represents a year-over-year decline from the $0.75 diluted EPS from the same quarter last year. HP did not provide a revenue outlook in its fiscal 2026 second-quarter press release, which is concerning since that's a critical detail investors should know amid the AI boom.
Today's Change
(
-7.27
%) $
-30.93
Current Price
$
394.32
The final verdict HP has a place for people who want value stocks. Dell is riskier due to its run-up and elevated P/E ratio compared to HP. However, Dell trades at a higher valuation because it is the better company.
Investors who want more exposure to AI and higher potential returns should prioritize Dell. Its AI servers are producing significant year-over-year revenue growth and are poised to build on that momentum for the rest of the year. Dell's guidance was also more compelling than what HP offered to its investors.
Dell's valuation should get more attractive as it continues to deliver high revenue growth and boost its net profit margins. Dell's net profit margin almost reached 8% in its fiscal 2027 first quarter compared to a 4.13% net profit margin in the same quarter last year.
Toyota (NYSE:TM | TM Price Prediction) and Ford (NYSE:F) closed very different earnings cycles. Toyota wrapped fiscal 2026 with $323.62 billion in revenue and a global hybrid engine humming across five brands. Ford posted a $43.25 billion Q1 and raised its 2026 outlook, yet the story underneath is a U.S. truck franchise carrying an EV division still bleeding cash.
Hybrid Cash Machine Meets a Truck-Powered Turnaround Toyota’s electrified mix hit 48.1% of retail sales, with BEV volumes up 68.4% to 243 thousand units. That mix, plus a Financial Services segment that grew operating income 24.6% to $5.44 billion, helped absorb an $8.81 billion U.S. tariff hit. Operating cash flow landed at $34.94 billion.
Ford’s quarter leans on Blue and Pro. Ford Blue revenue rose 14% to $23.9 billion, powered by F-Series, Bronco, and Expedition. Ford Pro delivered $1.69 billion EBIT with paid software subs up 30% YoY to 879,000. Model e lost $777 million, and a $1.30 billion IEEPA tariff benefit flattered results.
Business Driver Toyota Ford Main Growth Engine Hybrids and Lexus premium F-Series, Bronco, Ford Pro software Management Focus Cost reform, SDV, value chain Ford+ plan, Universal EV platform Key Drag U.S. tariffs, China margin Model e losses, aluminum costs Global Insulation vs. a Narrower U.S. Bet Toyota earns roughly $132.70 billion in North America but balances that with $50.71 billion in Japan, $50.41 billion in Asia, and $40.84 billion in Europe. Ford is heavily U.S.-anchored, amplifying commodity and tariff swings. Jim Farley framed it bluntly: “We built the foundation for a more modern, resilient Ford, improving cost and quality and building our world-class team.” Model e guidance calls for a $4.0 billion to $4.5 billion loss this year.
Valuation frames the divergence. Toyota trades at a 9 trailing P/E with a 3.65% dividend yield and a 0.306 beta. Ford’s $0.15 quarterly payout is generous, but Q1 free cash flow was negative $1.87 billion.
The Next Test Is Who Compounds Through Tariffs Toyota guided FY2027 operating income down 20.3% to JPY 3.0 trillion, absorbing more tariff pain and Middle East drag. Ford raised 2026 adjusted EBIT guidance to $8.5 billion to $10.5 billion. Watch whether Toyota’s BEV ramp to 598 thousand units lands without eroding hybrid margins, and whether Ford’s Universal EV platform narrows Model e losses before commodity headwinds hit their $2 billion peak.
Why I Lean Toyota for Cash Flow and Sleep-at-Night Ownership Toyota is the more resilient business. The hybrid franchise generates cash Ford’s EV unit still consumes, and the global footprint softens shocks hitting Ford’s Michigan-heavy P&L directly. Ford’s Blue and Pro segments offer real optionality with raised guidance. Toyota offers durable free cash flow, a 0.823 price-to-book, and a dividend backed by $80.83 billion in cash. The setup weakens only if Model e losses shrink faster than Toyota’s tariff drag deepens.
Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Toyota didn't make the cut. Grab the names FREE today.
SummaryMcKesson (MCK) is rated a buy, offering capital growth and dividend potential, underpinned by robust top-line and EPS growth. MCK's diversified portfolio, role in oncology and collaboration with big pharma names like AbbVie, and investment-grade Fitch rating support its investment case despite negative equity. Valuation appears compelling, with MCK trading at a forward earnings multiple of ~18x and estimated 18–22% upside by March 2028. Key risks include supply-chain disruptions and negative equity, but dividend growth, a conservative payout ratio, and sector scale mitigate concerns. Tom Werner/DigitalVision via Getty Images
Overview: An Investment-Grade, Major Medical Supplier in the US A compelling growth idea I found this month is major healthcare supplier McKesson (MCK), who beat earnings estimates in early May, and was reported
1.84K Followers
Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
Berkshire Hathaway (BRKA +1.14%)(BRKB +1.40%) is widely followed for its investment approach, which includes buying companies outright and buying shares of publicly traded companies. However, holding cash is also an investment decision, and at the end of the first quarter of 2026, Berkshire Hathaway had nearly $400 billion in cash. It would be better if CEO Greg Abel could find attractive investment opportunities for that cash, but that cash isn't dead money anymore.
The good and the bad of cash Former Berkshire Hathaway CEO Warren Buffett had a pretty simple concept around cash: If he couldn't find anything worth buying, he would hold cash. Buffett would rather wait than buy something just to buy something. Abel, his hand-picked successor, appears to have a similar mindset, noting that the cash balance rose in the single quarter that he was at the helm.
Image source: Getty Images.
That cash will be valuable during the next bear market, providing the business with a cushion. It will also give Abel the wherewithal to step in and buy while others are fearful and selling, effectively allowing the CEO to buy attractive assets while they are on sale. From this perspective, noting that the S&P 500 index (^GSPC +0.00%) is trading near all-time highs, investors should be pleased with the balance sheet positioning of Berkshire Hathaway.
The flip side of that argument is that the cash would likely yield higher returns if invested. That's true, but only if it is invested wisely. If Buffett and now Abel couldn't find anything worth buying, it is better for the money to sit in cash. A few years ago, while interest rates were near historical lows, holding cash was a real burden. But today, interest rates are higher, and cash is providing reliable low single-digit returns, with the Fed's target range for the federal funds rate currently set at 3.5% to 3.75%.
The news could get better on this front, as well. Although the new Fed chief, Kevin Warsh, had been talking about cutting rates before his appointment, the rate was held steady after his first Fed meeting. And the indication appears to be that rates will remain at current levels or perhaps rise. So Berkshire Hathaway's huge cash hoard could actually generate more income in the future, noting that the company largely holds short-term U.S. Treasury Bills ($339 billion at the end of the first quarter).
Today's Change
(
1.40
%) $
6.97
Current Price
$
506.71
As those government bonds roll over, Berkshire Hathaway buys new ones at the current rate. That step up in yield should happen fairly quickly, as Treasury Bills have durations that range from four weeks to a year. So the company's cash is a safety valve, a source of capital, and, increasingly, a valuable source of income. Getting paid more to wait for the right investment to come along is hard to complain about.
Berkshire Hathaway could be attractive if you are worried about the market Berkshire Hathaway is a very unique and complex company. However, if you are worried about the market's lofty levels, Berkshire Hathaway's huge cash pile could actually be a reason to buy the stock. That cash isn't the drag it once was, and it sets CEO Abel up to buy when others, perhaps including you, are fearful.
Mark Alan Peterson, EVP & Chief Financial Officer, reported an open-market sale of 8,334 shares of EPR Properties (EPR +2.18%) for a total consideration of ~$500,000, according to the SEC Form 4 filing.
Transaction summaryMetricValueShares sold (indirect)8,334Transaction value$500,040Post-transaction shares (direct)0Post-transaction shares (indirect)207,750Post-transaction value (direct ownership)$0Transaction value based on SEC Form 4 reported price ($60.00). EPR closed at $58.85 on the transaction date, June 10th 2026.
Key questionsHow does this transaction compare to Peterson’s historical sale sizes?
This 8,334 share sale is at the lower end of Peterson’s historical sell-only transactions, which have ranged from 8,334 to 13,700 shares, reflecting a declining trend as available share capacity has diminished over time.Does the transaction affect Peterson’s overall economic exposure to EPR Properties?
Despite the sale, Peterson continues to hold 207,750 shares indirectly through the Jill J. Peterson Rev. Trust, maintaining substantial economic exposure to the company through convertible Common Shares of Beneficial Interest.What is the significance of the 10b5-1 trading plan in this context?
This sale was effected under a Rule 10b5-1 trading plan adopted on Dec. 23, 2025, indicating the disposition was pre-scheduled and consistent with routine liquidity management rather than market timing.How does the transaction value relate to recent market pricing?
The $60.00 per share sale price was slightly above the June 10, 2026 closing price of $59.36, representing a ~1.1% premium to the closing level on the transaction date.Company overviewMetricValueRevenue (TTM)$718 millionNet income (TTM)$275 millionDividend yield5.39%1-year price change8.3%Note: 1-year price change calculated as of July 1, 2026.
Company snapshotEPR owns and leases a portfolio of experiential real estate assets, including entertainment, recreation, and education properties across 44 U.S. states.It operates as a specialty REIT utilizing a net lease model, generating revenue primarily through long-term rental agreements with tenants in leisure and recreational sectors.The company serves operators of out-of-home entertainment venues, recreational facilities, and specialty education centers seeking stable, high-quality real estate solutions.EPR Properties manages a diversified portfolio valued at approximately $6.7 billion, focusing on properties that facilitate unique consumer experiences. The company’s disciplined underwriting and investment approach targets assets with resilient cash flows and long-term growth potential. This specialization in experiential real estate provides EPR Properties with a distinct competitive advantage in the specialty REIT sector.
What this transaction means for investorsPeterson's sale was pre-scheduled back in December, and it priced slightly above where EPR shares were trading that day, so there's little to read into the timing itself. The more useful question for investors is what has to keep going right for EPR's growth story to hold up. The company just raised its 2026 earnings guidance and expanded its investment spending target to as much as $600 million, largely to fund a $315 million push into attraction properties including a portfolio acquired from Six Flags. That's a bet that regional parks and similar destinations keep pulling in reliable foot traffic even as EPR leans away from its old core of movie theaters. The company's occupancy across its experiential portfolio sat at 99% last quarter, which suggests tenants are performing well enough to support the expansion. The risk is concentration: a handful of tenants still make up a large share of EPR's rental income, so any stumble from a major operator would matter more here than at a more diversified REIT. I like this company for the long haul, and at current levels I think it's worth starting a position or adding a little if you already own it. One thing worth considering: REIT dividends are typically taxed as ordinary income, so where you hold this stock matters. If you're building a position, a Roth IRA can be a smart home for it, since it lets those dividends and any future gains grow and come out tax-free.
Seena Hassouna has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends EPR Properties. The Motley Fool has a disclosure policy.
Choosing between Dyne Therapeutics (DYN +5.87%) and Recursion Pharmaceuticals (RXRX +3.54%) requires balancing the potential of targeted muscle-tissue therapies against the broad, data-driven power of artificial intelligence in drug discovery.
Dyne Therapeutics focuses on solving delivery challenges for neuromuscular diseases, while Recursion Pharmaceuticals aims to industrialize drug discovery through its proprietary digital platform. Both companies represent high-risk, high-reward opportunities within the healthcare sector for investors seeking clinical-stage innovation.
The case for Dyne TherapeuticsDyne Therapeutics operates in the field of biotech stocks by developing therapeutics that target muscle and the central nervous system. Its proprietary Forces platform aims to deliver medicine directly to affected tissues to treat conditions like Duchenne muscular dystrophy (DMD). The company relies on a loan agreement with Hercules Capital (HTGC +0.25%) as its only committed source of external capital. Customer concentration like this adds a layer of risk to the business.
The company had no revenue in FY 2025 because it is still in the development stage. Dyne reported a net loss of $446.2 million for the period, compared to a net loss of $317.4 million the prior year. This increasing loss reflects the rising costs associated with moving multiple candidates through clinical trials. High research spending is common for companies at this stage of development.
Its debt-to-equity ratio is close to 0.0x, indicating a minimal reliance on borrowed funds relative to shareholder equity. Free cash flow for FY 2025 was nearly negative $405.1 million. Free cash flow is cash from operations minus capital expenditures, which represents the money left after paying for business maintenance.
Recursion Pharmaceuticals is building an AI-native discovery platform to identify new investigational medicines across oncology and rare diseases. The company generates revenue through strategic collaborations with large partners like Roche, Genentech, and Takeda Pharmaceutical Co (TAK +5.14%). It also maintains technical relationships with Bayer, Merck & Co (MRK +3.34%), Sanofi SA (SNY +3.67%), and Nvidia (NVDA 1.39%). These partnerships provide necessary capital and validation for its proprietary digital operating system.
In FY 2025, revenue reached approximately $74.7 million, representing nearly 27% growth over the previous fiscal year. Despite this growth, the company reported a net loss of nearly $645 million for the same period.
As of its December 2025 balance sheet, the company maintained a debt-to-equity ratio of near 0.1x, indicating a strong position to meet short-term liabilities. Free cash flow for the period was approximately negative $378 million, reflecting the high costs of maintaining its data-generation capabilities and proprietary hardware.
Risk profile comparisonDyne Therapeutics faces significant liquidity risks and anticipates needing substantial additional funding to support its research pipeline. The company is highly dependent on meeting specific clinical and regulatory milestones to access remaining loan tranches from its lenders. Furthermore, it relies entirely on third-party suppliers for critical components, creating operational vulnerability. Any failure in clinical trials or the termination of intellectual property licenses with partners such as the University of Mons could significantly impact the business.
Recursion Pharmaceuticals relies entirely on the success of its AI platform to identify viable drug candidates. There is no guarantee that AI-driven discoveries will translate into successful clinical outcomes or regulatory approvals. The company also faces integration risks following its acquisition of Exscientia, which could impact its financial results if synergies are not realized. Continued operating losses may lead to shareholder dilution if the company must issue more stock to raise capital.
Valuation comparisonRecursion Pharmaceuticals carries a significant premium relative to its current revenue. Dyne Therapeutics, meanwhile, has neither of these ratios because it is not expected to generate revenue in 2026 and didn’t in 2025.
MetricDyne TherapeuticsRecursion PharmaceuticalsSector BenchmarkForward P/En/an/a389.1xP/S ration/a26.8xSector benchmark uses the SPDR XLV sector ETF.
Valuation metrics sourced from Financial Modeling Prep (FMP) and may differ from other data providers.
Which stock would I buy in 2026?Dyne Therapeutics may not have revenue, but its $3.7 billion market cap is a sign of investors’ faith in the business. Dyne is preparing its first product for Duchenne Muscular Dystrophy to enter the market in the first quarter of fiscal 2027, with its second product, DM1, expected to come to market in 2028
Long-term revenue projections are inherently more speculative, but analysts see Dyne making $53 million in sales in 2027 and $277 million in 2028, and reaching well over $1 billion in 2030. That’s a great outlook.
Recursion is also a development-stage firm with a $2 billion market cap, but its product revenue appears further off. Right now, the business generates annual revenue through milestone payments from development partners like Sanofi. That revenue is expected to be lower in 2026. The business is making progress with its AI-based discovery platform. In the first quarter, management touted its first clinical proof of concept with its polyp-related treatment, REC-4881 allosteric MEK1/2 inhibitor focused on FAP. It showed a significant reduction in precancerous polyps, a major driver of the disease’s progressive nature. Still, significant revenue for the business is seen as years away.
Both companies are more speculative buys, given that they require regulatory approvals and have greater capital needs. But given Dyne appears closer to getting its first treatment to market, it gets the nod
New York, New York--(Newsfile Corp. - July 4, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of AeroVironment, Inc. (NASDAQ: AVAV) between June 25, 2025 and March 10, 2026, inclusive (the "Class Period"), of the important July 27, 2026 lead plaintiff deadline.
SO WHAT: If you purchased AeroVironment securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
WHAT TO DO NEXT: To join the AeroVironment class action, go to https://rosenlegal.com/cases/aerovironment-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 27, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.
DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) AeroVironment understated the likelihood that it would imminently face competition from other vendors for the work it performed in connection with the U.S. Space Force's Satellite Communication Augmentation Resources ("SCAR") program and the U.S. Space Force's ongoing efforts to modernize the Satellite Control Network ("SCN"); (2) accordingly, defendants overstated AeroVironment's business and financial prospects; and (3) as a result, defendants' public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
To join the AeroVironment class action, go to https://rosenlegal.com/cases/aerovironment-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.
Attorney Advertising. Prior results do not guarantee a similar outcome.
-------------------------------
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/303848
Source: The Rosen Law Firm PA
Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.
New York, New York--(Newsfile Corp. - July 4, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of FS KKR Capital Corp. (NYSE: FSK) between May 8, 2024 and February 25, 2026, inclusive (the "Class Period"), of the important July 6, 2026 lead plaintiff deadline.
SO WHAT: If you purchased FS KKR Capital securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
WHAT TO DO NEXT: To join the FS KKR Capital class action, go to https://rosenlegal.com/submit-form/?case_id=64089 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 6, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.
DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) FS KKR Capital overstated the effectiveness of its portfolio restructuring efforts for its nonaccrual companies; (2) FS KKR Capital overstated the valuation of its portfolio investments and/or overstated the effectiveness of FS KKR Capital's portfolio valuation process; (3) FS KKR Capital overstated the durability of its quarterly distribution strategy; and (4) as a result of the foregoing, defendants' positive statements about FS KKR Capital's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.
To join the FS KKR Capital class action, go to https://rosenlegal.com/submit-form/?case_id=64089 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.
Attorney Advertising. Prior results do not guarantee a similar outcome.
-------------------------------
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/303887
Source: The Rosen Law Firm PA
Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.
Healthcare is changing through AI and personalized cell therapy. Which of these high-growth innovators represents the better risk-adjusted opportunity for your portfolio today as you evaluate Heartflow Inc. (HTFL 9.05%) and Iovance Biotherapeutics (IOVA +8.56%)?
Heartflow focuses on non-invasive AI diagnostics for heart disease, while Iovance develops personalized cell therapies to treat solid tumors. Both companies are scaling commercial operations in high-stakes medical fields, offering investors exposure to cutting-edge clinical technology. This comparison evaluates their financial health and market risks to determine which aligns best with your investment strategy.
The case for Heartflow Inc.Heartflow sells AI-enabled software designed to analyze coronary artery disease. The company provides these tools to clinicians to help identify blockages more accurately than traditional tests. Heartflow currently maintains about 1,465 accounts in the U.S. and is expanding its reach among healthcare stocks by focusing on its core FFR CT Analysis product, which generates nearly 98% of its revenue.
In FY 2025, revenue reached about $176 million, a 40% increase over the prior year. Despite this strong top-line expansion, the business reported a net loss of $116.8 million for the period.
As of its December 2025 balance sheet, the debt-to-equity ratio is approximately 0.1x. This ratio compares total debt to shareholders’ equity, indicating a low level of borrowing relative to shareholders’ equity. Free cash flow, calculated as cash from operations minus capital expenditures, was nearly negative $59.0 million for the year.
Iovance Biotherapeutics develops personalized tumor-infiltrating lymphocyte therapies to treat patients with cancer. The company generates revenue by selling its primary products, Amtagvi and Proleukin, to hospitals, clinics, and specialized distributors. To support its pipeline, Iovance maintains critical license agreements with major organizations, including Novartis AG (NVS +3.74%) and Cellectis SA (CLLS +12.24%), while operating its own centralized manufacturing facility.
During FY 2025, the company reported revenue of $263.5 million, reflecting a significant 60.6% growth rate over the prior year. This increase followed the successful commercial scaling of its lead therapies across North American markets. However, the company recorded a net loss of roughly $391 million, slightly deeper than 2024.
According to its December 2025 balance sheet, Iovance maintains a debt-to-equity ratio of approximately 0.1x. Free cash flow for fiscal year 2025 was negative $336.2 million, reflecting the heavy capital requirements of personalized cell therapy manufacturing and clinical trials.
Risk profile comparisonHeartflow relies on a single product for 98% of its revenue, creating significant concentration risk. The company is also cooperating with a U.S. Department of Justice investigation regarding its marketing activities and financial arrangements with providers. Furthermore, the proposed 2026 Medicare rules suggest a 15% reduction in reimbursement for its core service, while competition remains intense from GE HealthCare Technologies Inc (GEHC +1.15%), Siemens, and Philips (PHG +1.98%).
Iovance faces substantial financial risk with an accumulated deficit of $2.9 billion as of March 31, 2026. The manufacturing process for its therapies is highly complex and patient-specific, which poses risks of contamination or supply chain failure. Additionally, the company is managing the aftermath of a 19% workforce reduction intended to extend its cash runway, which may impact its long-term operational capacity and growth initiatives.
Valuation comparisonNeither company is seen making a profit in 2026, so neither has a forward price-to-earnings ratio.
MetricHeartflow Inc. Common StockIovance BiotherapeuticsSector BenchmarkForward P/En/an/a389.1xP/S ratio13.8x5.3xSector benchmark uses the SPDR XLV sector ETF.
Valuation metrics sourced from Financial Modeling Prep (FMP) and may differ from other data providers.
Which stock would I buy in 2026?Heartflow is in the early stages of its commercialization. Heartflow’s use of AI to assist doctors in detecting heart blood flow blockages non-invasively is real-world proof of AI’s ability to improve patients’ lives. The company boasts the largest proprietary set of medical images on which to base its forthcoming autonomous diagnostic tool. Heartflow says it has 200 million doctor-annotated images to teach its AI. It, however, isn’t expected to generate positive free cash flow until 2028.
Iovance saw first-quarter 2026 revenue rise 45% year over year to 71.4 million, and management expects second-quarter sales to be up about 23% from the same period in 2025. It, too, is expected to turn cash flow positive in 2028. Over time, it expects total sales of Amtagvi and Proleuken to each surpass $1 billion, making them both blockbusters in pharma investor parlance.
Each business is exciting in its own way. Iovance Biotherapeutics gets the nod over Heartflow by virtue of its lower price-to-sales ratio under the guide of buy good companies at good prices.
The first half of the trading year typically operates on a dominant market narrative. Over the past six months, that narrative has favored massive artificial intelligence (AI) and compute infrastructure rallies. By July, those storylines can start to lose momentum as investors reassess crowded trades and look for the next source of market breadth.
As Q3 institutional window dressing concludes, portfolio managers have already locked in their first-half performance for client statements and are actively resetting their risk models. Some institutional investors may be looking for a specific setup right now: asymmetric risk-reward in sectors starved of capital.
Get Joby Aviation alerts:
Institutions may be quietly cutting dead weight, locking in gains from crowded technology sector trades, and positioning ahead of the next major market rotation. The goal for investors is to front-run this institutional capital flow by targeting fundamentally sound companies anchored by large backlogs, concrete government contracts, and technical mean-reversion setups.
Multiple Compression: The Math Catching Up to TechMega-cap technology and pure-play AI software trades are historically crowded and mathematically overextended. The momentum concentrated in these names relied on late-stage multiple expansion that cannot sustain itself indefinitely.
When a software business trades at 30 times forward sales, investors demand perfection in operational execution just to maintain current price levels. Any slight miss in forward guidance or revenue acceleration triggers margin compression.
Capital allocators recognize this structural vulnerability. Any broadening of market breadth leaves these hyper-valued names susceptible to rapid pullbacks. Funds are actively rotating out of these exhausted narratives to find hard assets in the physical economy, hunting for tangible value over speculative growth.
Taking Flight: Assembly Lines Replace R&D DreamsThe advanced aviation sector is shedding its origins in speculative research and development to become a heavily capitalized, federally certified manufacturing industry. Institutional capital favors operational milestones over conceptual designs.
Joby Aviation Today
$8.44 -0.05 (-0.53%)
As of 07/2/2026 03:59 PM Eastern
This is a fair market value price provided by Massive. Learn more.
52-Week Range$7.75▼
$20.95Price Target$13.64
Joby Aviation NYSE: JOBY recently provided a strong catalyst for scaled commercial production. Filings from late June formalize a strategic manufacturing alliance with Toyota Motor Corporation NYSE: TM.
Toyota Motor Corporation now holds a 13.1% beneficial ownership stake and established a 51% controlling interest in the newly formed preparation enterprise dedicated to manufacturing Joby Aviation aircraft. Backed by a $500 million direct investment, this capital structure de-risks the commercial scale-up process. The transition shifts Joby Aviation from a visionary concept to a tangible operational business with an automotive sector giant running the factory floor.
Conversely, Archer Aviation NYSE: ACHR presents a textbook technical mean-reversion setup. Despite a 35% year-to-date drawdown, Archer Aviation's underlying balance sheet is a fortress. Archer Aviation retains $1.78 billion in cash and short-term investments, yielding a current ratio exceeding 18x.
Institutional capitulation often signals a technical bottom. Prominent growth funds recently offloaded heavy blocks of Archer Aviation shares near 52-week lows, flushing out weak hands. Rapid progress through Federal Aviation Administration type certification and government integration programs validates the operational timeline, making the current discount an attractive accumulation zone before regulatory clearance is priced in.
Monopolizing Orbit: The New Vertical Space RaceThe commercial space economy is currently transitioning from niche experimental launches to scaled telecom and infrastructure duopolies. Billions in government subsidies and mergers are permanently altering sector valuation models.
Rocket Lab Today
$100.46 0.00 (0.00%)
As of 07/2/2026 04:00 PM Eastern
52-Week Range$35.25▼
$151.00Price Target$108.24
Rocket Lab NASDAQ: RKLB recently announced an $8 billion cash-and-stock acquisition of Iridium Communications. The broader market has yet to fully price in the extent to which this alters the Rocket Lab corporate valuation model.
By acquiring Iridium Communications, Rocket Lab vertically integrates into a space services powerhouse, securing high-margin recurring telecom revenue to offset the cash burn traditionally associated with launch segments. Supported by a 63.5% year-over-year increase in Q1 top line to $200.3 million and a record $2.2 billion backlog, Rocket Lab is mispriced following recent broader technology selloffs.
A unique market dynamic is unfolding for Intuitive Machines NASDAQ: LUNR. Short sellers frequently target capital-intensive space equities, assuming management will heavily dilute shareholders to fund operations. Currently, 28.85% of Intuitive Machines' public float is sold short.
However, Intuitive Machines recently secured a firm-fixed-price NASA Commercial Lunar Payload Services contract valued up to $148.3 million. Securing massive non-dilutive government contracts to deliver lunar payloads provides a predictable revenue floor that breaks down the bearish thesis. The technical setup currently favors short-squeeze mechanics driven by forced institutional covering on operational execution.
AST SpaceMobile NASDAQ: ASTS offers a high-beta momentum play as it nears the commercialization of its direct-to-cell satellite constellation. AST SpaceMobile maintains a strong liquidity profile with roughly $3.5 billion in cash runway. A recent $926 million subsidy from the Japanese government to deploy a domestic satellite network with Rakuten OTCMKTS: RKUNY validates the technology on a sovereign level. Capital rotation into space-based telecom will continue driving upward price pressure for AST SpaceMobile.
Plugging in: The Backdoor AI Infrastructure PlayFuelCell Energy Today
$28.11 0.00 (0.00%)
As of 07/2/2026 04:00 PM Eastern
52-Week Range$3.78▼
$37.88Price Target$22.00
Data centers require immense amounts of uninterrupted baseload power. Traditional energy grids are entirely tapped out, creating an urgent macro tailwind for grid-independent energy solutions. FuelCell Energy NASDAQ: FCEL is well-positioned as a backdoor play on artificial intelligence infrastructure. The narrative surrounding FuelCell Energy has shifted from legacy green energy to essential hyperscaler baseload power.
The realization of 12.5 MW standardized energy block demand for data centers, paired with a $49 million U.S. EXIM Bank financing package, fundamentally transforms FuelCell Energy's balance sheet.
Recent forced index buying catalyzed double-digit percentage spikes following the addition of FuelCell Energy to the Russell 2000. Heavily beaten down in the first half of the year, FuelCell Energy now offers a technical mean-reversion setup backed by critical physical demand.
Act Before the Crowd: Finalizing a Hardware StrategyPositioning portfolios for the back half of the year requires identifying structural shifts before they dominate financial headlines. The transition away from overextended software multiples into tangible hardware, government backlogs, and de-risked manufacturing joint ventures offers a highly favorable asymmetric profile.
Allocating capital toward fundamentally sound businesses anchored by technical downside protection remains the most effective strategy to capture the impending Q3 institutional rotation. Let the smart money show you where the physical economy is heading, and act confidently before the window closes.
Should You Invest $1,000 in Joby Aviation Right Now?Before you consider Joby Aviation, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Joby Aviation wasn't on the list.
While Joby Aviation currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.
Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.
Quantum computing's potential to accelerate complex computations opens a new frontier of technological innovation. Investors have piled into quantum computing stocks in anticipation of the investment opportunities quantum computing could create over the next decade.
D-Wave Quantum (QBTS 4.15%), an early-stage quantum computing company that's begun ramping up its commercial operations, has been one of the hottest names in the space. Shares of D-Wave Quantum have traded between $12 and $46 over the past year and currently sit somewhere near the middle at $24 per share. With the business building momentum, is the stock a buy now? Here's why investors may want to hold off for now.
Image source: Getty Images.
The business is building momentum, but it's still early D-Wave Quantum is developing annealing and gate-model quantum computer systems, software, and services for commercial applications. The company hasn't generated much revenue to date, as quantum computers aren't yet reliable enough for everyday commercial applications. The business is just getting started, with trailing-12-month revenue of just $12.4 million.
That said, D-Wave Quantum's order backlog took a big leap in the first quarter of 2026. The company sold a computer system to Florida Atlantic University for $20 million. It inked a $10 million agreement with a Fortune 100 customer for cloud-based access to quantum computing, which investors could think of as quantum computing-as-a-service.
Every contract D-Wave Quantum wins moves the needle at this stage, when the numbers are this small. As it stands now, analysts estimate that D-Wave Quantum will generate approximately $42.5 million in revenue this fiscal year, followed by $86.1 million the next.
Meanwhile, investors must still grapple with a steep valuation Perspective is especially important when talking about a stock with a market cap of $8.4 billion. D-Wave Quantum is trading at roughly 200 times Wall Street's revenue estimates for this year, and 100 times next year's estimate. That makes D-Wave Quantum one of Wall Street's most expensive names, and that's assuming the company hits those revenue numbers over the next 18 months.
Today's Change
(
-4.15
%) $
-0.97
Current Price
$
22.52
Typically, investors want to pay up for dominant companies with explosive growth. Sure, D-Wave Quantum could grow quickly from here, but that growth is coming on tiny numbers. The reality is that landing a couple of deals isn't nearly enough to give investors confidence that D-Wave Quantum can sustain its success.
It's also unclear just how D-Wave Quantum will slot into the industry's competitive landscape. There are other pure-play quantum computing companies, as well as deep-pocketed tech giants, developing their own technologies and systems. Investors who buy now are essentially banking on a best-case scenario, such as D-Wave Quantum becoming an industry leader. Investors won't know much until the broader quantum computing industry is much further along.
Right now, there's far more room for the stock to decline from there than to rise. Therefore, D-Wave Quantum is not a buy at the moment.
Sandisk (SNDK 14.13%) is the best-performing S&P 500 stock so far in 2026, and it isn't particularly close. It's up around 800% so far in 2026, easily outperforming second-place Micron Technology, which is up "only" about 300%. That's a simply incredible performance for just six months.
Still, after a run like that, it's reasonable to wonder if there is further upside ahead or if Sandisk has delivered everything that it's going to deliver in 2026.
Although it may seem surprising, I think there is plenty of upside left in Sandisk's stock in the second half of 2026, especially with the major shortages going on in its industry. While it won't return another 800% from here, it could still reward investors quite well.
Image source: The Motley Fool.
The memory chip shortage is getting worse Sandisk makes NAND memory, which is primarily utilized for long-term data storage. Most of the NAND memory you'll encounter in a data center comes in the form of solid-state drives (SSDs), which are used for long-term information storage. Sandisk and its peers aren't used to the massive demand being generated by data centers, and this cohort doesn't have the production capacity necessary to meet demand. As a result, prices for memory chips are soaring, and Sandisk is benefiting from it.
Today's Change
(
-14.13
%) $
-287.22
Current Price
$
1745.00
Everyone in the industry is scrambling to stand up more capacity, but it may be a losing battle. Micron, another memory chip maker, believes that "tight conditions" will persist beyond 2027, which bodes well for the demand curve Sandisk is seeing.
Compounding this is a rapidly expanding data center build-out plan; Nvidia believes global data center spending could reach $3 trillion to $4 trillion annually by 2030. That creates an environment where Sandisk and its peers can succeed for a long time, making the stock an intriguing buy.
Wall Street analysts project major growth ahead for Sandisk, with fiscal fourth-quarter growth of 336% (ended in June) and 122% growth for fiscal 2027. As long as the stock is reasonably priced, this means Sandisk stock could easily go higher from here, and fortunately for investors, it is. I'm using fiscal 2027 estimates to value Sandisk's stock, since it just started:
SNDK PE Ratio (Forward 1y) data by YCharts
At 11 times fiscal 2027 earnings, Sandisk stock isn't very expensive, and could easily double from here and still be reasonably valued. As a result, I think Sandisk could head higher from today's levels, and makes for a great buy now.
Three weeks ago, Elon Musk's artificial intelligence (AI) and space infrastructure goliath, Space Exploration Technologies (SpaceX) (SPCX +2.69%), etched its name in Wall Street's record books.
Prior to SpaceX, no public company had ever raised more than $29.4 billion from an initial public offering (IPO), including the underwriters' option. SpaceX practically tripled this figure by raising $85.7 billion from its June 12 IPO. It also made SpaceX one of America's largest businesses.
But it'll take a lot more than IPO buzz and history-making moments to convince Wall Street that SpaceX is a stock retail investors should own. Despite several upcoming catalysts, including SpaceX's inclusion in the growth-focused Nasdaq-100, a massive potential fleecing of retail investors awaits, courtesy of the company's accelerated share lockup period.
Image source: Getty Images.
In addition to the largest-ever IPO capital raise, SpaceX's debut was unique in how few shares the company sold. While the 555.6 million shares sold might sound like a lot, it's less than 5% of the company's outstanding shares. Typically, companies that are going public sell 10% to 25% of their outstanding shares.
SpaceX's historically low float (i.e., tradable shares), coupled with forced buying by index funds -- SpaceX was or will be added to the Russell 1000, Russell 3000, and Nasdaq-100 -- can artificially boost its share price.
But this tailwind for SpaceX stock has a rapidly approaching end date. Once Musk's AI and space conglomerate reports its first quarterly operating results as a public company, currently estimated for Aug. 6, the clock starts ticking for insiders (high-ranking executives, board members, and early investors) to sell their shares.
The lockup for SpaceX shares is like nothing I have ever seen.
Three groups with different lockup regimes.
The largest group has 180 day lockup after IPO, but with a graduated ability to sell based on share price at milestones before then. pic.twitter.com/LvoVGML0F0
-- Adam Rossi (@rossiadam) May 23, 2026 For early release-eligible shares, insider sales can begin two trading days following the first quarterly report. Here's the full breakdown for the early release unlock schedule:
After two full trading days following the first public quarterly report (20% of early release shares) If SpaceX stock is 30% (or more) above its IPO price for five of 10 trading days ending on the second trading day after the first report (10%) Calendar day 70 after its June 12 IPO (7%) Calendar day 90 after IPO (7%) Calendar day 105 after IPO (7%) Calendar day 120 after IPO (7%) Calendar day 135 after IPO (7%) After two full trading days following its second public report in November (28%) Calendar day 180 after IPO (7%) On calendar day 366 after SpaceX's IPO, all remaining shares are eligible to be sold. This includes the shares held by CEO Elon Musk.
In other words, one of the largest wealth transfers in Wall Street's storied history, from SpaceX insiders to unsuspecting retail investors, is roughly a month away from commencing.
Not only will early release-eligible insiders have a clear path to cash in, but SpaceX's prospectus also outlined the likelihood of debt and equity capital raises for the foreseeable future. This can result in share-based dilution that provides added downside pressure on SpaceX stock.
Even with several early catalysts, SpaceX stock looks to be a landmine for retail investors.
Sean Williams has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
Cory Johnson talks about Anthropic ahead of its and OpenAI's upcoming IPOs. On SpaceX (SPCX), Cory argues that “what's best for millionaire Elon Musk, may not be the best for everyone else,” explaining that big indexes buying into the stock takes away price discovery for peers.
SummaryThese are the first REITs I would buy today.Near-term headwinds have created rare discounts.AI could turn today’s laggards into future winners.High Yield Landlord members get exclusive access to our real-world portfolio. See all our investments here » mattjeacock/iStock via Getty Images
A question I often get asked is:
If you had to start from scratch, what REITs would you buy first today?
And it makes sense. A lot of you have not held any REITs in recent
69.66K Followers
Analyst’s Disclosure: I/we have a beneficial long position in the shares of REXR; RYN either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
The AI arms race has entered a new phase. For the past three years, the biggest technology companies have competed by buying as many Nvidia (NASDAQ:NVDA | NVDA Price Prediction) GPUs as they could get their hands on. Now they’re racing to build something even more valuable: their own AI chips.
That shift is about more than lowering costs. It gives hyperscalers greater control over performance, supply chains, and the pace of innovation. Meta Platforms (NASDAQ:META) appears ready to take another major step in that direction with a reported $6.5 billion agreement that could strengthen its long-term AI ambitions while reshaping the semiconductor landscape.
Meta Is Building More Than Just Another AI Chip According to reports from Korean media, Meta is negotiating a roughly $6.5 billion agreement with Samsung Foundry to manufacture its third-generation Meta Training and Inference Accelerator (MTIA) processors. Unlike the first two MTIA generations, which were built by Taiwan Semiconductor Manufacturing (NYSE:TSM), the new chips would be produced using Samsung’s cutting-edge 2-nanometer SF2 manufacturing process featuring Gate-All-Around (GAA) transistor technology.
The scale of the reported agreement stands out. The contract reportedly covers hundreds of thousands of semiconductor wafers, making it one of Samsung Foundry’s largest AI orders after its reported $16.5 billion Tesla (NASDAQ:TSLA) agreement.
The supplier change is just as important as the technology.
MTIA Generation Manufacturing Partner Strategic Focus First Generation TSM Launch custom AI silicon Second Generation TSM Expand AI inference capabilities Third Generation (reported) Samsung Foundry Diversify supply chain and adopt 2nm process This isn’t simply about building faster chips. It’s about ensuring Meta can keep expanding its AI infrastructure without depending on a single manufacturing partner.
Why This Matters for Meta’s AI Strategy Meta has made no secret of its AI ambitions. CEO Mark Zuckerberg has said the company plans to invest hundreds of billions of dollars in AI infrastructure while targeting as much as 5 gigawatts of computing capacity by 2030. That scale demands more than buying Nvidia hardware — it requires custom silicon optimized for Meta’s own Llama models and recommendation engines.
Custom chips also improve economics. NVIDIA’s GPUs remain the gold standard for AI training, but they command premium pricing and face periodic supply constraints. By designing its own accelerators, Meta can tailor performance to its workloads while reducing dependence on outside suppliers.
Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Meta didn't make the cut. Grab the names FREE today.
Looking ahead, these chips could support something even bigger. As Meta expands into AI cloud services, proprietary hardware could become a competitive advantage, much like Amazon‘s (NASDAQ:AMZN) AWS built custom Graviton processors or Google developed its Tensor Processing Units (TPUs).
The Bigger Trend Investors Should Watch Meta isn’t acting alone. Alphabet (NASDAQ:GOOG), Amazon, Microsoft (NASDAQ:MSFT), and Tesla have all invested heavily in custom AI silicon. The common goal is simple: reduce long-term infrastructure costs while differentiating their AI platforms.
That doesn’t spell the end for Nvidia. Training frontier AI models will continue requiring enormous numbers of GPUs for years. But inference — the process of actually running AI models — and specialized workloads increasingly favor application-specific chips that consume less power and cost less to operate.
Samsung also benefits if the reported agreement closes. After trailing TSM in advanced manufacturing for years, landing another hyperscaler on its 2nm process would strengthen its credibility and help build momentum for its foundry business.
Key Takeaway In short, Meta’s reported $6.5 billion Samsung agreement is about far more than changing chip suppliers. It’s another sign that the largest AI companies are shifting from buying generic hardware to building customized infrastructure designed around their own software.
Granted, Nvidia remains the dominant force in AI accelerators, and custom chips won’t replace its GPUs overnight. That said, investors should recognize the broader trend. The AI chip market is becoming more fragmented, with hyperscalers increasingly controlling their own destinies.
Ultimately, Meta’s reported move strengthens its long-term competitive position by lowering supply chain risk, improving cost control, and supporting future cloud ambitions. For long-term shareholders, that’s the real story — and one worth following well beyond the latest headline.
Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Meta didn't make the cut. Grab the names FREE today.
The company will be renting excess computing capacity, and that is big news for two reasons.
*Stock prices used were the afternoon prices of July 1, 2026. The video was published on July 3, 2026.
Parkev Tatevosian, CFA has positions in Meta Platforms. The Motley Fool has positions in and recommends Meta Platforms. The Motley Fool has a disclosure policy. Parkev Tatevosian is an affiliate of The Motley Fool and may be compensated for promoting its services. If you choose to subscribe through his link, he will earn some extra money that supports his channel. His opinions remain his own and are unaffected by The Motley Fool.
A large percentage of AI stocks already trade at a rich premium. So despite these companies' promising long-term revenue growth potential, investors may not profit as much as they predict.
To realize the biggest profits, AI investors must find AI stocks trading at low valuations. This is easier said than done. The trick isn't necessarily to buy out-of-favor AI stocks -- as very few exist at this time -- but to find stocks that the market doesn't yet realize are AI stocks. This way, investors can buy into AI stocks without the AI stock premium.
After falling 20% in value since 2026, the business below looks like a promising bet for AI investors looking to avoid the AI premium.
The market still doesn't appreciate this is an AI stock Rivian Automotive (RIVN +8.44%) is my favorite AI stock for the second half of 2026. But wait, isn't Rivian an electric vehicle (EV) stock? It is. But just like Tesla, the company has pivoted hard toward AI to power its autonomous driving ambitions.
Today's Change
(
8.44
%) $
1.45
Current Price
$
18.63
At one time, the market did appreciate Rivian's AI pivot. Last year, from Nov. 4 to Dec. 19, shares nearly doubled in value. What was the cause? The surge was at least partially due to the company's first "AI Day," which was held on Dec. 11.
During that event, Rivian announced several key strategy shifts. The company's future would no longer be tied simply to producing consumer-grade vehicles. Instead, technology would become the unmistakable focus. For example, Rivian now plans to produce its own AI chips, invest so heavily into self-driving software that it no longer expects to be profitable by 2027, and integrate AI more heavily into its production process to reduce costs and improve throughput.
Image source: Getty Images.
Quite quickly, however, the hype surrounding Rivian's AI event faded. Shares have lost nearly one-third of their value since Dec. 19. But when you look at the numbers, there's plenty of reason to remain bullish. This year, analysts expect sales to grow by around 31%. Next year, sales growth should jump to 64%.
This growth is largely due to Rivian's launch of its first affordable vehicle priced under $50,000: its R2 SUV. Production and sales growth are just now beginning to scale. Long-term, however, Rivian's pivot to AI is already paying off. In March -- just a few months after its first AI event -- Uber Technologies placed a $1.25 billion order for up to 50,000 Rivian R2s. Uber wants to scale its own robotaxi service. And it's apparently so bullish on Rivian's technology that it wanted to make sure it could secure plenty of vehicles as that business emerges.
It's not yet clear how this order will translate into accounting revenue, given it was structured as a direct investment. But it's a clear sign that well-funded robotaxi operators like what they see coming out of Rivian. Rivian shares still trade at just 3.4 times sales. As its AI pivot gains traction, expect that valuation to improve.
My cost basis on NVIDIA (NASDAQ:NVDA | NVDA Price Prediction) keeps climbing, and I keep adding anyway. The stock dropped 12.46% over the past month. I bought. It closed the most recent session at $194.83, down 1.39% on the day. I bought again.
This is the position I cannot stop building, because the company running under the ticker is powering what its CEO calls “the largest infrastructure expansion in human history.”
The pull is simple. NVIDIA sells the compute every serious AI project needs, and the buyers show up with sovereign-sized checkbooks. Meta committed to millions of Blackwell and Rubin GPUs.
OpenAI signed for at least 10 gigawatts of NVIDIA systems. Anthropic started with 1 gigawatt of Grace Blackwell and Vera Rubin. CoreWeave is building 5+ gigawatts of AI factories by 2030. That customer list looks like a toll road under the AI economy.
Here is why the buy button stays warm Growth is accelerating. Q1 FY2027 revenue hit $81.61B, up 85.2% year over year, beating the estimate by 3.16%. Non-GAAP EPS of $1.87 beat by 5.42%, the fourth consecutive beat. Data Center alone did $75.25B, up 92%. Networking inside that segment ran $14.8B, up 199%. Management guided Q2 to $91B.
Margins and cash flow are the second reason. Non-GAAP gross margin sits at 75%, up from 60.8% a year ago. Operating income hit $53.54B, up 147.42%. Free cash flow in a single quarter was $48.55B, up 85.41%. Full fiscal 2026 delivered $96.58B in free cash flow on $215.94B of revenue. Shareholders’ equity of $195.47B stands against just $64B of total liabilities.
Don't wait: the analyst who called NVIDIA in 2010 just revealed his top 10 AI stocks. See the full list FREE now.
Third, management is returning cash to me. The board raised the quarterly dividend from $0.01 to $0.25, a 25x increase, and authorized another $80B in buybacks on top of $38.5B already remaining. Roughly $20B was returned to shareholders in Q1 alone. Supply commitments climbed to $119B, which reads to me as demand already booked.
The Real Risk China. H20 shipments went to zero in the quarter versus $4.6B in the year-ago period, and Q2 guidance excludes any China Data Center compute revenue. Export restrictions are real, and TSMC concentration adds a single point of manufacturing dependency.
I have sat with this. My conviction holds because the rest of the world is buying so aggressively that the company still guided to $91B for next quarter with a zero from China baked in. If restrictions ease, that is upside I am not paying for.
Valuation is the fair pushback. Trailing P/E is 30, forward P/E is 23, PEG is 0.616. For a business compounding revenue at 85% with 75% gross margins and $48B of quarterly free cash flow, those numbers work for me. The consensus analyst target sits at $301.62. Polymarket traders cluster the July outcome at $192 with a 98% probability of closing above $140.
I keep buying because the AI factory buildout is early, the customer commitments are contractual, the cash is real, and the board is sending it back. Every dip is the market handing me a discount on the same thesis I owned last quarter. The buy button stays live.
Don't wait: the analyst who called NVIDIA in 2010 just revealed his top 10 AI stocks. See the full list FREE now.
Visa (V +2.87%) has historically been a market-beating stock, but it's been struggling this year, and investors are noticing several headwinds. The stock is down 2% this year, compared with a 9% increase for the S&P 500. Is this a buying opportunity?
The world's tollbooth Visa is the largest credit card network in the world, with more than $17 trillion in payments processed last year and more than 330 billion transactions. It works with 14,500 partnering financial institutions that provide credit, while Visa provides the network that moves the money, taking a small fee from each transaction. It acts as a global "tollbooth" for payments, a service-oriented business that generates high revenue and strong profits.
This is a classic "cash cow" business, with Visa in a dominant position and high barriers to entry. Its network is entrenched in global payments, and it continually adds new services to its platform as finance enters the digital age.
Image source: Getty Images.
In the 2026 fiscal second quarter (ended March 31), revenue increased 17% year over year, while adjusted earnings per share (EPS) were up 20%. Those are powerful results, especially in the high-inflation climate.
However, the market isn't seeing it that way. There are several headwinds, specifically in the rise of stablecoins, which challenge the Visa global network, and legislation related to interchange rates. Stablecoins bypass the Visa rails, and the Credit Card Competition Act (CCCA) threatens to lower fees and break up the Visa-Mastercard duopoly.
On top of that, cross-border volume has been trending down over the past few quarters since it bounced back from pandemic lows.
Is Visa stock a bargain at this price? Visa has a strong economic moat and a dominant position by far. It has an excellent, profitable business model that makes it an important part of the global economy, and it has a robust innovation engine. These are prized features, and Visa stock is typically expensive because of them.
Today's Change
(
2.87
%) $
10.07
Current Price
$
361.15
At the current price, Visa stock trades at a price-to-earnings (P/E) ratio just under 30, which is slightly below recent averages (31 over the past three years) and much lower than historical averages (35 over the past 10 years). It's a good deal, but not an incredible bargain.
Visa is an excellent, all-weather stock to own for the long term. At this price, I'd call it a great business at a fair price, which is how Warren Buffett looks for stocks. It was part of the Berkshire Hathaway portfolio for years until Greg Abel recently sold it, and it could be a great stock to add to a diversified portfolio at the current price.
Jennifer Saibil has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Berkshire Hathaway, Mastercard, and Visa. The Motley Fool has a disclosure policy.
Several companies are approaching the $1 trillion valuation milestone, with only a modest increase in market capitalization needed to join the ranks of the world’s trillion-dollar companies.
Based on current valuations, analyst sentiment, and business fundamentals, Finbold has identified two stocks that stand out as the most likely candidates to hit a $1 trillion market cap in 2026.
The companies are already valued near the threshold. Their strong earnings outlooks, established market positions, and favorable analyst expectations make them leading contenders among the next $1 trillion stocks.
Walmart (NASDAQ: WMT) Retail giant Walmart (NASDAQ: WMT) currently commands a market capitalization of roughly $890 billion, putting it less than 13% away from the $1 trillion mark.
The company’s proximity to the milestone is one of the strongest arguments in its favor. Walmart has already approached the valuation threshold at various points in 2026, meaning a relatively modest rise in its share price could be enough to push it over the line.
WMT one-week stock price chart. Source: Finbold Beyond its size, Walmart continues to benefit from a resilient retail business, growing e-commerce operations, and expanding investments in artificial intelligence. The company has been using AI to improve supply chain efficiency, enhance customer personalization, and support growth in its Walmart+ membership ecosystem.
Analysts also expect continued revenue and earnings growth, supported by strong performance across its U.S. stores and Sam’s Club operations. Share buybacks and a long history of dividend payments further strengthen its investment appeal.
While Walmart’s premium valuation leaves less room for operational missteps, its defensive business model and exposure to consumer staples provide a degree of protection during periods of economic uncertainty.
JPMorgan Chase (NYSE: JPM) JPMorgan Chase (NYSE: JPM) is another leading candidate among stocks to hit a $1 trillion market cap in 2026.
The banking giant is valued at approximately $896 billion, meaning it needs a gain of about 12% to reach the milestone. That places it among the closest publicly traded companies to the trillion-dollar threshold.
JPM one-week stock price chart. Source: Finbold JPMorgan’s diversified business model remains a key advantage. The company generates revenue from consumer banking, investment banking, trading, wealth management, and asset management, helping it navigate different economic environments.
The bank has consistently reported strong earnings, supported by healthy net interest income, fee generation, and solid credit quality.
Its ongoing investments in digital banking and artificial intelligence are also expected to improve efficiency and productivity over time.
Analysts generally maintain a bullish outlook on the stock, citing JPMorgan’s strong balance sheet, consistent profitability, and shareholder-friendly capital return programs, including dividends and buybacks.
Potential risks include interest rate volatility, regulatory changes, and a weaker economic environment.
However, the bank’s scale and market leadership position it well to continue growing toward the trillion-dollar milestone.
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Netflix (NASDAQ: NFLX | NFLX Price Prediction) and Walt Disney (NYSE: DIS) just reported quarters showing two opposite business models behind the same word: streaming. Netflix delivered an asset-light cash haul. Disney posted a record parks quarter and streaming profitability inflection, but carried a heavy capital bill. The contrast matters as discretionary budgets tighten.
Netflix Squeezes Cash. Disney Buys Cruise Ships. Netflix put up Q1 2026 revenue of $12.25 billion, up 16.19% year over year, and free cash flow of $5.09 billion on just $196.1 million of capex. The ad tier drew over 60% of sign-ups in ads markets, with advertiser count climbing 70% to more than 4,000 clients. A $2.8 billion Warner Bros. termination fee juiced the headline, but the operating engine was already humming.
Disney’s Q2 FY2026 told a different story. Revenue reached $25.17 billion, up 6.55%, with adjusted EPS of $1.57 beating the $1.4955 estimate. Entertainment SVOD operating income surged 88% to $582 million, hitting a 10.6% margin for the first time. Experiences set a Q2 record at $9.49 billion. The catch: capex of $1.97 billion and net income that fell 24.73% year over year.
Business Driver Netflix Disney Quarterly capex $196M $1.97B FY operating margin target 31.5% 10% SVOD Main growth engine Ads + price hikes Parks + SVOD inflection One Walks Away. One Doubles Down. Netflix collected its breakup check, restarted buybacks, and stayed disciplined. The company repurchased 13.5 million shares for $1.3 billion with $6.8 billion still authorized, and raised 2026 free cash flow guidance to roughly $12.5 billion. Japan led the quarter, with the World Baseball Classic becoming the most-watched Netflix program ever in that country.
Disney went the other way. ESPN acquired NFL Network for a 10% noncontrolling interest in ESPN, Hulu Live TV merged into Fubo at 70% Disney ownership, and the Disney Adventure cruise launched in Singapore. FY2025 capex hit $8.02 billion, a 48% jump. Sports operating income is expected to decline roughly 14% year over year in Q3 on programming costs.
The Next Test Is Sticky Inflation Watch whether Disney’s per capita parks growth, up 5% domestically, holds as gasoline spending climbed to $552.8 billion in May 2026 from $415.7 billion in January. Recreation services spending hit $862.3 billion in May 2026, a dataset high, which favors couch entertainment over plane tickets. Netflix’s content amortization is expected to peak in Q2 2026, so margin expansion in the back half is the real proof point.
Why Netflix’s Cash Machine Wins Netflix edges Disney here. The streaming wars are effectively over and Netflix won, and the numbers back that read: a 31.5% operating margin target against a Disney SVOD business that just crossed 10.6%. NFLX is down 21.31% year to date, so the market is pricing in tougher comps. For diversified entertainment exposure, Disney offers a broader mix of parks, sports, and streaming assets. For insulated, capital-light cash generation, Netflix is the cleaner story, even after a rough six months.
Want Up To $1,000? SoFi Is Giving New Active Invest Users Free StockLooking to grow your money but unsure where to begin? SoFi Active Invest is offering a limited-time promotion—open an account, fund it with $50 or more, and you could receive up to $1,000 in complimentary stock for Active Invest accounts.
From $0 commission trading to fractional shares and automated investing, this app is designed to simplify investing for everyone, whether you’re just starting or already experienced. Its easy to sign up and secure your bonus.
Target can retain its advantage over Walmart and Costco with its lower P/E ratio and higher dividend yield. Unforced errors and declining sales pressured Target and its stock over the last few years.
Dividend Kings, companies with at least 50 consecutive years of dividend increases, are the quiet backbone of an income portfolio. Heading into July, three of them stand out for different reasons: One is the textbook compounding consumer staple, one is a turnaround with a catalyst on the clock and one is the high-yield income workhorse.
Here is the bull case for each.
Procter & Gamble (NYSE: PG) Procter & Gamble (NYSE:PG | PG Price Prediction) is the cleanest Dividend King in the group. The company just delivered its 70th consecutive annual dividend increase and has paid a dividend every year since 1890. At a recent price of $151.08, the stock yields roughly 3% and trades at a forward P/E of 21x.
The bull case is operational momentum. Q3 FY26 was the fourth consecutive top- and bottom-line beat, with core EPS of $1.59 against a $1.5552 estimate and net sales of $21.23 billion, up 7% year over year. Growth was broad: Beauty +11%, Grooming +7%, Health Care +7%, Fabric & Home Care +7%. CEO Shailesh Jejurikar described “a solid acceleration in top-line results…broad-based growth across product categories and regions.” Management plans to return roughly $10 billion in dividends and $5 billion in buybacks in FY26 and Wall Street’s average target sits at $163.52.
Risk: tariffs and commodities. P&G is absorbing a ~$400 million after-tax tariff headwind and ~$150 million commodity headwind, with core gross margin compressed 100 basis points. Guidance now points to the lower end of the $6.83 to $7.09 core EPS range.
Genuine Parts (NYSE: GPC) Genuine Parts (NYSE:GPC), the parent of NAPA, is the catalyst trade. Shares have ripped 20% in the past month to $117.67, yet the stock remains roughly flat year over year. The dividend streak now stands at 70 consecutive years, with the quarterly payout raised 3% to $1.0625, good for a yield near 4%.
The bull case has three legs. First, Q1 FY26 results came in “ahead of expectations,” with adjusted EPS of $1.77 on $6.26 billion in revenue and Industrial EBITDA margin expanding 90 basis points to 14%. Second, the planned tax-free separation into two independent public companies, Global Automotive and Global Industrial, is targeted for Q1 2027, and CEO Will Stengel called it a step “expected to unlock value for our stakeholders.” Third, DA Davidson initiated coverage with a Buy rating and a $145 target on June 23, citing the spin-off and NAPA cost-cutting. Forward P/E is just 15x.
Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and P&G didn't make the cut. Grab the names FREE today.
Risk: execution. Q4 2025 missed badly at $1.55 adjusted EPS versus $1.81 expected, hit by a $741.97 million non-cash pension settlement charge and a $150.5 million credit loss tied to the First Brands supplier bankruptcy. The next read is Q2 2026 earnings on July 21.
Altria (NYSE: MO) Altria (NYSE:MO) is the yield play. At $72.74, the stock pays a 6% dividend yield, trades at a trailing P/E of 15x, and has hiked the payout 60 times in the past 56 years. The most recent quarterly dividend was $1.06, paid July 10, 2026.
The bull case is cash flow. Q1 FY26 adjusted diluted EPS landed at $1.32 versus $1.25 expected, with revenue of $5.43 billion, up 20% year over year. Smokeable adjusted operating income rose 6% to $2.68 billion on pricing and contract manufactured export volume. CEO Billy Gifford said the company “delivered a strong start to the year, growing adjusted diluted EPS by 7% in the first quarter.” Altria returned $8 billion to shareholders in 2025 and reaffirmed FY26 adjusted EPS guidance of $5.56 to $5.72. Shares are up nearly 27% year to date.
Risk: secular cigarette volume decline. Domestic cigarette industry volume fell roughly 5%, Marlboro retail share slipped 1 point to 40%, and on! nicotine pouch share dropped 4 points to 13%. With NJOY ACE blocked by the ITC and not returning in 2026, the next-gen pivot remains the long-term overhang on an otherwise generous payout.
Three Different Roles for One Income Sleeve Each fills a distinct role. P&G offers compounding quality at a premium multiple. Genuine Parts offers value with a defined corporate catalyst into 2027. Altria offers a near-6% yield with structural decline priced in. For July positioning, the GPC earnings report on July 21 is the most immediate event to monitor, followed by P&G’s FY26 close and any update on tariff pass-through.
Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and P&G didn't make the cut. Grab the names FREE today.
$750 billion is the round-number scale the market now attaches to the AI infrastructure wave rolling through NVIDIA (NASDAQ:NVDA | NVDA Price Prediction), Alphabet (NASDAQ:GOOG), and Oracle (NYSE:ORCL).
The evidence sits in three data points from the most recent quarterly filings. NVIDIA’s Q2 FY2027 revenue guide of $91.0 billion, Alphabet’s 2026 capex guide of $180 billion to $190 billion, and Oracle’s remaining performance obligations of $638 billion, up 363% year over year. Add those together and the spending is real, contractual, and rolling forward.
What It Means These are the mechanics of a capital cycle already in motion.
NVIDIA reported Q1 FY2027 revenue of $81.61 billion, up 85.2% year over year, with Data Center alone at $75.25 billion and Data Center Networking up 199%. Alphabet’s Google Cloud grew 63% to $20.03 billion, with backlog nearly doubling quarter over quarter to over $460 billion. Oracle’s cloud infrastructure revenue rose 93% to $5.79 billion, and management booked $67 billion in AI infrastructure contracts in a single quarter, with global GPU utilization at 97.5%.
Jensen Huang framed the moment in one line: “The buildout of AI factories, the largest infrastructure expansion in human history, is accelerating at extraordinary speed.”
Market Reaction The three stocks have diverged in 2026. NVIDIA is up 6.07% year to date through July 1, closing at $197.58. Alphabet is up 14.2% at $357.89. Oracle is down 26.02% at $142.50, weighed down by a capex cycle that produced negative $23.69 billion in free cash flow.
Don't wait: the analyst who called NVIDIA in 2010 just revealed his top 10 AI stocks. See the full list FREE now.
Bull Case NVIDIA is compounding at scale. Non-GAAP gross margin held at 75.0%, net income grew 210.63%, operating income grew 147.42%, and free cash flow reached $48.55 billion in the quarter. The board authorized an additional $80 billion share buyback, returned roughly $20 billion to shareholders in Q1, and raised the dividend from $0.01 to $0.25 per share. Notably, supply-related commitments of $119.0 billion signal the runway.
Alphabet had a similar story. The company’s Q1 EPS of $5.11 topped consensus of $2.63 by 94.10%. Operating income rose 29.70%, operating margin expanded to 36.1%, and Gemini now processes 16 billion tokens per minute via API, up 60% from the prior quarter. Impressively, paid subscriptions reached 350 million, and the dividend rose 5% to $0.22 per share. Free cash flow fell 46.63% as capex more than doubled, a tradeoff CFO Anat Ashkenazi described directly: “We are seeing unprecedented internal and external demand for AI compute resources.”
Oracle sits at the sharpest edge of the trade. RPO of $638 billion gives multi-year revenue visibility, with $75 billion tied to prepaid or customer-supplied GPU arrangements that reduce Oracle’s own capital load. Multicloud AI Database revenue grew 404% in Q4. FY2027 guidance points to a $90 billion revenue target and non-GAAP EPS of $8.05, with Q1 cloud growth guided to 58% to 64%. The offset: Oracle plans to raise roughly $40 billion in FY2027 through debt and equity to fund the buildout, on top of $218.70 billion in existing liabilities.
Bottom Line The $750 billion figure captures a spending cycle already showing up in reported revenue, contracted backlog, and forward guidance. For long-term holders, the three stocks offer different angles on the same theme. NVIDIA sells the shovels at 75.0% non-GAAP gross margin. Alphabet monetizes its own stack while renting compute to enterprises at 36.1% operating margin. Oracle is levering the balance sheet to catch up, with a backlog that has grown 363% to prove the demand. The near-term catalysts are calendared: Oracle’s Q1 FY2027 report on September 10, 2026, followed by Oracle Investor Day on October 28, 2026 in Las Vegas, will test whether the RPO converts on schedule. The number is set. The question long-term investors face is which balance sheet finishes best.
Don't wait: the analyst who called NVIDIA in 2010 just revealed his top 10 AI stocks. See the full list FREE now.
There are several macro trends that I have high conviction in. However, there are also several sectors that are positioned to benefit immensely from these macro trends that the market has recently sold off. I detail why I am bullish on these sectors and some high-yielding funds that are well-positioned to benefit.
Micron Technology (MU 5.68%) once again turned in a spectacular quarter when it reported its fiscal third-quarter results after the bell on June 24. While the stock initially surged, it has since given back most of its gains. The stock is still up around 236% on the year.
Let's dig into the memory maker's results and prospects to see whether the artificial intelligence (AI) stock is a buy.
Micron is hitting on all cylinders Micron is one of the three major DRAM (dynamic random-access memory) manufacturers, and it has been benefiting from soaring DRAM and NAND (flash) memory prices, as both remain in short supply due to the data center build-out. Over 75% of Micron's revenue comes from DRAM, with the rest largely from NAND.
Image source: The Motley Fool.
The DRAM market is being fueled by the need for high-bandwidth memory (HBM), packaged with AI chips such as graphics processing units (GPUs) to optimize performance. The fast-growing inference market, meanwhile, tends to be even more memory-intensive than AI model training, further driving demand dynamics. Micron's HBM supply is booked out through 2027 and into 2028, and it sees the total addressable market reaching $100 billion in 2027.
It noted that the industry outlook for both the DRAM and NAND markets is that demand will continue to significantly outpace supply. It said that supply challenges for HBM and DRAM, in particular, remain "severe." It upped its capital expenditure (capex) budget to $27 billion this fiscal year as it begins construction on new greenfield projects to increase supply.
Overall, for its fiscal third quarter, Micron reported that its revenue increased from $9.3 billion to $41.5 billion, easily surpassing the $35.8 billion consensus, as compiled by LSEG.
By segment, cloud memory revenue surged fourfold to $13.8 billion, while core data center revenue climbed from $1.5 billion in the year-ago period to $11.5 billion. Mobile revenue jumped from $3.3 billion to $11.5 billion, while automotive and embedded revenue rose from $1.1 billion to $4.6 billion. Gross margins surged to 84.6%, up from just 37.7% a year ago, and were up from 74.4% in fiscal Q2.
Adjusted earnings per share (EPS) came in at $24.67 compared to $1.68 a year ago. That was well above the $20.78 adjusted EPS analysts expected.
Looking ahead, Micron guided for fiscal Q4 revenue of around $50 billion with gross margins of approximately 86%. The company is looking for adjusted EPS of about $30.73 at the midpoint.
Today's Change
(
-5.68
%) $
-58.69
Current Price
$
973.59
Despite its continued surging revenue and gross margin expansion, Micron stock remains cheap, trading at a forward price-to-earnings (P/E) ratio of 7 times fiscal 2027 analyst estimates. While historically a boom-and-bust cyclical business, the company now has about 40% of its revenue locked up in long-term strategic customer agreements. At the same time, there are a few signs that the memory market will be in supply-demand balance anytime soon, given the surge in AI infrastructure spending and demand.
As such, the stock looks attractive at current levels.
Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of Class A or Class C common stock of Zillow Group, Inc. (NASDAQ: ZG) (NASDAQ: Z) between February 11, 2025 and May 7, 2026, both dates inclusive (the "Class Period"), of the important August 10, 2026 lead plaintiff deadline in the securities class action first filed by the Firm.
So what: If you purchased Zillow common stock during the Class Period, you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
What to do next: To join the Zillow class action, go to https://rosenlegal.com/cases/zillow-group-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 10, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.
Details of the case: According to the lawsuit, defendants throughout the Class Period made materially false and/or misleading statements and/or failed to disclose that: (1) Zillow's agreement with Redfin Corporation was not a "partnership," but rather an acquisition of Redfin's business; (2) as a result of the Redfin Agreement, Zillow faced a materially heightened risk of regulatory scrutiny and liability under federal antitrust laws; (3) upon the filing of an antitrust lawsuit, Zillow continued to downplay its legal exposure; and (4) as a result, defendants' statements about Zillow's business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
To join the Zillow class action, go to https://rosenlegal.com/cases/zillow-group-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.
Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com